[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1165
1. Han HS, Chang CB, Seong SC, Lee S, Lee MC: Evaluation of anatomic references for tibial sagittal alignment in total knee arthroplasty. Knee Surg Sports Traumatol Arthrosc; 2008 Apr;16(4):373-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of anatomic references for tibial sagittal alignment in total knee arthroplasty.
  • Angles between the mechanical axis (MA), the tibial anatomical axis (TAA), the anterior tibial cortex (ATC) and the fibular shaft axis (FSA) were measured, and then medial and lateral tibial slope angles were measured using all axes.
  • Mean angles between MA and the other anatomical reference lines (TAA, ATC and FSA) were 0.9, 2.2 and -2.1 degrees, respectively.
  • The mean values of lateral tibial slopes with respect to MA, TAA, ATC and FSA were 8.7, 10, 12 and 7.3, respectively, and their intra- and inter-observer reliabilities were higher than those of medial tibial slopes.

  • MedlinePlus Health Information. consumer health - Knee Replacement.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Br. 2002 Aug;84(6):858-60 [12211678.001]
  • [Cites] Clin Orthop Relat Res. 2003 Nov;(416):177-84 [14646759.001]
  • [Cites] J Orthop Sci. 2005;10 (1):42-7 [15666122.001]
  • [Cites] Rev Chir Orthop Reparatrice Appar Mot. 1996;82(3):195-200 [9005456.001]
  • [Cites] Clin Orthop Relat Res. 1991 Aug;(269):63-9 [1864058.001]
  • [Cites] Clin Orthop Relat Res. 1996 Oct;(331):102-6 [8895625.001]
  • [Cites] J Arthroplasty. 2000 Feb;15(2):224-7 [10708090.001]
  • [Cites] J Arthroplasty. 1988;3 Suppl:S51-7 [3199140.001]
  • [Cites] J Orthop Res. 1989;7(1):132-7 [2908904.001]
  • [Cites] J Arthroplasty. 1987;2(4):317-26 [3430160.001]
  • [Cites] J Arthroplasty. 1998 Aug;13(5):552-8 [9726321.001]
  • [Cites] Am J Sports Med. 2005 Mar;33(3):378-87 [15716253.001]
  • [Cites] Acta Orthop Scand. 2004 Oct;75(5):573-9 [15513489.001]
  • [Cites] J Radiol. 1993 Jan;74(1):27-33 [8483148.001]
  • [Cites] J Bone Joint Surg Am. 2004 Mar;86-A(3):506-11 [14996875.001]
  • [Cites] J Bone Joint Surg Br. 2003 Aug;85(6):830-5 [12931800.001]
  • [Cites] Z Orthop Ihre Grenzgeb. 2003 Mar-Apr;141(2):143-7 [12695949.001]
  • [Cites] Clin Orthop Relat Res. 2004 Sep;(426):180-6 [15346071.001]
  • [Cites] Clin Orthop Relat Res. 2002 Apr;(397):424-33 [11953637.001]
  • [Cites] J Bone Joint Surg Am. 2000 Nov;82-A(11):1603-8 [11097451.001]
  • [Cites] Clin Orthop Relat Res. 2004 Sep;(426):194-8 [15346073.001]
  • [Cites] Rev Chir Orthop Reparatrice Appar Mot. 1993;79(8):625-34 [7938808.001]
  • [Cites] J Arthroplasty. 1996 Jan;11(1):99-103 [8676126.001]
  • [Cites] J Arthroplasty. 2005 Apr;20(3):282-8 [15809943.001]
  • [Cites] Knee Surg Sports Traumatol Arthrosc. 2001 Sep;9(5):296-8 [11685361.001]
  • [Cites] Knee Surg Sports Traumatol Arthrosc. 2005 Jan;13(1):38-43 [15045163.001]
  • [Cites] J Bone Joint Surg Br. 2004 Aug;86(6):818-23 [15330021.001]
  • [Cites] Knee Surg Sports Traumatol Arthrosc. 2005 Apr;13(3):193-6 [15824934.001]
  • [Cites] Am J Sports Med. 2004 Mar;32(2):376-82 [14977661.001]
  • [Cites] Am J Knee Surg. 1999 Summer;12(3):165-8 [10496466.001]
  • [Cites] J Arthroplasty. 2000 Oct;15(7):916-20 [11061453.001]
  • [Cites] Arthroscopy. 2004 Apr;20(4):366-72 [15067275.001]
  • [Cites] Biomed Tech (Berl). 2003 Dec;48(12 ):339-43 [14740521.001]
  • (PMID = 18270685.001).
  • [ISSN] 0942-2056
  • [Journal-full-title] Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA
  • [ISO-abbreviation] Knee Surg Sports Traumatol Arthrosc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


2. Bhatia A, Rao A, Ang KK, Garden AS, Morrison WH, Rosenthal DI, Evans DB, Clayman G, Sherman SI, Schwartz DL: Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy. Head Neck; 2010 Jul;32(7):829-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy.
  • BACKGROUND: The aim of this study was to review institutional outcomes for anaplastic thyroid cancer treated with conformal 3-dimensional radiotherapy (3DRT) or intensity-modulated radiotherapy (IMRT).
  • Patients without distant metastases receiving >or=50 Gy had superior survival outcomes; 5 such patients had no evidence of disease at last follow-up.
  • CONCLUSIONS: Outcomes for anaplastic thyroid cancer treated with 3DRT or IMRT remain equivalent to historical results.
  • Healthy patients with localized disease who tolerate full dose irradiation can potentially enjoy prolonged survival.
  • [MeSH-major] Radiotherapy, Intensity-Modulated. Thyroid Neoplasms / mortality. Thyroid Neoplasms / radiotherapy


3. Olthof M, Persoon AC, Plukker JT, van der Wal JE, Links TP: Anaplastic thyroid carcinoma with rhabdomyoblastic differentiation: a case report with a good clinical outcome. Endocr Pathol; 2008;19(1):62-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic thyroid carcinoma with rhabdomyoblastic differentiation: a case report with a good clinical outcome.
  • Anaplastic thyroid carcinoma is a rare and highly malignant disease.
  • Usually, this type of tumor is irresectable, and almost all patients die within 1 year after diagnosis.
  • We present a case of anaplastic thyroid carcinoma with rhabdomyoblastic differentiation and good therapeutic outcome.
  • Biopsy of the mass showed microscopically and immunohistochemically a follicular (Hürthle cell) carcinoma of the thyroid, dedifferentiated to an anaplastic carcinoma with divergent differentiation along rhabdomyoblastic cell lines.
  • After a follow-up of 3 years, the patient still remains in a good condition without any signs of recurrent disease.
  • Other cases of rhabdomyoblastic and rhabdoid anaplastic thyroid carcinomas have been described.
  • Both types of carcinoma are associated with an aggressive clinical course.
  • In our case, the patient is still alive without evidence of disease 3 years after primary therapy.
  • The good clinical outcome of our patient suggests that surgical resection, radiotherapy, and I-131 ablation therapy with curative intent seems to be an adequate treatment option in patients with anaplastic thyroid carcinoma with rhabdoid and rhabdomyoblastic differentiation.
  • [MeSH-major] Carcinoma / pathology. Rhabdomyosarcoma / pathology. Thyroid Neoplasms / pathology. Thyroidectomy
  • [MeSH-minor] Aged. Cell Differentiation. Combined Modality Therapy. Female. Humans. Iodine Radioisotopes / therapeutic use. Radiotherapy / methods. Thyroglobulin / blood. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1990 Jul 15;66(2):321-30 [1695118.001]
  • [Cites] Semin Diagn Pathol. 1985 May;2(2):123-36 [3843690.001]
  • [Cites] Pathol Res Pract. 2006;202(1):55-9 [16310972.001]
  • [Cites] Wien Klin Wochenschr. 1980 Feb 15;92(4):122-7 [7395228.001]
  • [Cites] Virchows Arch. 2005 Jan;446(1):46-51 [15517365.001]
  • [Cites] Am J Surg Pathol. 2007 May;31(5):729-36 [17460457.001]
  • [Cites] Am J Clin Pathol. 1987 Apr;87(4):434-42 [2435145.001]
  • [Cites] Ann Acad Med Singapore. 1996 May;25(3):413-9 [8876909.001]
  • [Cites] Endocr Pathol. 2006 Winter;17(4):399-405 [17525488.001]
  • [Cites] Am J Clin Pathol. 1985 Feb;83(2):135-58 [2578727.001]
  • [Cites] Laryngoscope. 1992 May;102(5):486-91 [1573942.001]
  • [Cites] Cancer. 1978 Jun;41(6):2267-75 [657091.001]
  • [Cites] Arch Pathol Lab Med. 2005 Mar;129(3):e55-7 [15737050.001]
  • (PMID = 18330722.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


Advertisement
4. Trimboli P, Ulisse S, Graziano FM, Marzullo A, Ruggieri M, Calvanese A, Piccirilli F, Cavaliere R, Fumarola A, D'Armiento M: Trend in thyroid carcinoma size, age at diagnosis, and histology in a retrospective study of 500 cases diagnosed over 20 years. Thyroid; 2006 Nov;16(11):1151-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trend in thyroid carcinoma size, age at diagnosis, and histology in a retrospective study of 500 cases diagnosed over 20 years.
  • Recently, the Italian Network of Cancer Registries analyzed 5101 cases of thyroid carcinoma showing a reduction of mortality rate of 4%/year.
  • This prompts us to evaluate the temporal trend in tumor size, age at diagnosis, and histology in a retrospective analysis of 500 thyroid cancers diagnosed over 20 years.
  • Thyroid cancers were divided in two groups.
  • In particular, papillary thyroid carcinoma (PTC) size decreased from 28 +/- 1.2mm to 14 +/- 0.8mm and follicular carcinoma from 40 +/- 6.3mm to 17 +/- 4.5 mm.
  • Age at diagnosis of all carcinomas increased significantly from 40 +/- 1.3 years in the first group to 48 +/- 0.9 years in the second group.
  • Analysis of the histological types revealed a significant increase of PTC rate in the second decade from 82% to 92% and a concomitant reduction of anaplastic thyroid carcinoma (ATC) from 3.7% to 1.0%.
  • In conclusion, it may be speculated that the above mentioned decreased mortality rate for thyroid carcinoma could be related to the significant reduction with time of cancer size, to the progressive increase of PTC rate and to the reduction of ATC rate.
  • These data, if confirmed in other series, underscore the importance of evaluating thyroid nodules smaller than 10mm and corroborate recent findings suggesting that age be reconsidered as an independent prognostic factor for differentiated thyroid cancers.
  • [MeSH-major] Carcinoma, Papillary / mortality. Carcinoma, Papillary / pathology. Thyroid Neoplasms / mortality. Thyroid Neoplasms / pathology
  • [MeSH-minor] Age Distribution. Carcinoma / mortality. Carcinoma / pathology. Cell Differentiation. Humans. Italy / epidemiology. Mortality / trends. Registries / statistics & numerical data. Retrospective Studies. Sex Distribution

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17123342.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Goodman A, Mensch JM, Jay M, French KE, Mitchell MF, Fritz SL: Retention and attrition factors for female certified athletic trainers in the National Collegiate Athletic Association Division I Football Bowl Subdivision setting. J Athl Train; 2010 May-Jun;45(3):287-98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retention and attrition factors for female certified athletic trainers in the National Collegiate Athletic Association Division I Football Bowl Subdivision setting.
  • However, little is known about the retention and attrition of female certified athletic trainers (ATs) in certain settings.
  • OBJECTIVE: To gain insight and understanding into the factors and circumstances affecting female ATs' decisions to persist in or leave the National Collegiate Athletic Association Division I Football Bowl Subdivision (NCAA D-I FBS) setting.
  • [MeSH-major] Athletic Injuries. Burnout, Professional. Football / injuries. Personnel Turnover / statistics & numerical data. Sports Medicine / manpower

  • MedlinePlus Health Information. consumer health - Sports Fitness.
  • MedlinePlus Health Information. consumer health - Sports Injuries.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nurs Health Sci. 2001 Sep;3(3):161-72 [11882192.001]
  • [Cites] Phys Ther. 2009 Sep;89(9):946-56 [19608632.001]
  • [Cites] J Allied Health. 1978 Fall;7(4):281-7 [10239353.001]
  • [Cites] Acad Manage J. 1981 Sep;24(3):543-65 [10252608.001]
  • [Cites] J Prof Nurs. 1991 Jul-Aug;7(4):221-7 [1894842.001]
  • [Cites] Physiother Can. 1993 Fall;45(4):239-44 [10130907.001]
  • [Cites] J Allied Health. 1996 Summer;25(3):219-32 [8884434.001]
  • [Cites] J Adv Nurs. 1997 Feb;25(2):245-56 [9043997.001]
  • [Cites] Int J Nurs Stud. 2006 Feb;43(2):237-63 [15878771.001]
  • [Cites] Int J Nurs Stud. 2007 Feb;44(2):297-314 [16631760.001]
  • [Cites] J Athl Train. 2008 May-Jun;43(3):275-83 [18523564.001]
  • [Cites] J Athl Train. 2008 Jul-Aug;43(4):373-8 [18668170.001]
  • [Cites] J Athl Train. 2008 Sep-Oct;43(5):505-12 [18833313.001]
  • [Cites] J Athl Train. 2008 Sep-Oct;43(5):513-22 [18833314.001]
  • [Cites] J Allied Health. 2002 Fall;31(3):131-9 [12227263.001]
  • (PMID = 20446843.001).
  • [ISSN] 1938-162X
  • [Journal-full-title] Journal of athletic training
  • [ISO-abbreviation] J Athl Train
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2865968
  •  go-up   go-down


7. Chiu CY, Wu YC, Jenq SF, Jap TS: Mutations in low-density lipoprotein receptor gene as a cause of hypercholesterolemia in Taiwan. Metabolism; 2005 Aug;54(8):1082-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We identified 6 mutations in LDLR gene, including heterozygous missense mutations I420T (ATC-->ACC), C660W (TGC-->TGG), H562Y (CAC-->TAC), and A606T (GCC-->ACC), and a heterozygous and a homozygous mutation in codon P664L (CCG-->CTG) as well as a homozygous large deletion of exons 6 to 8.

  • Genetic Alliance. consumer health - Hypercholesterolemia.
  • MedlinePlus Health Information. consumer health - Cholesterol.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16092059.001).
  • [ISSN] 0026-0495
  • [Journal-full-title] Metabolism: clinical and experimental
  • [ISO-abbreviation] Metab. Clin. Exp.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, LDL
  •  go-up   go-down


8. Abou Chakra CN, Pariente A, Pinet M, Nkeng L, Moore N, Moride Y: Case series in drug safety: a review to determine characteristics and quality. Drug Saf; 2010 Dec 01;33(12):1081-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adverse effects involved mainly the skin (18.5%) and the circulatory system (13.8%).
  • The main suspected drug classes (Anatomical Therapeutic Chemical classification) were nervous system drugs (23.1%) and antineoplastic and immunomodulating agents (20.0%).

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cutis. 2007 Sep;80(3):231-7 [17956013.001]
  • [Cites] Therapie. 2009 Jul-Aug;64(4):289-94 [19804709.001]
  • [Cites] Eye (Lond). 2007 Apr;21(4):547-9 [16456589.001]
  • [Cites] CMAJ. 2005 Mar 15;172(6):765-7 [15767610.001]
  • [Cites] J Rheumatol. 2008 Mar;35(3):537-8 [18203307.001]
  • [Cites] Drug Saf. 2006;29(8):687-96 [16872242.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2006 Nov;15(11):808-12 [16700082.001]
  • [Cites] Intern Med J. 2006 Mar;36(3):162-9 [16503951.001]
  • [Cites] J Ocul Pharmacol Ther. 2004 Apr;20(2):179-82 [15117574.001]
  • [Cites] J Mich Dent Assoc. 2005 Nov;87(11):44-9 [16372548.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2007 May;16(5):581-7 [17471601.001]
  • [Cites] Ann Intern Med. 2003 May 20;138(10):807-11 [12755552.001]
  • [Cites] Eur J Clin Pharmacol. 2001 Apr;57(1):89-91 [11372600.001]
  • [Cites] Drug Saf. 2007;30(5):367-73 [17472416.001]
  • [Cites] Cutan Ocul Toxicol. 2008;27(1):5-9 [18330828.001]
  • [Cites] Drug Saf. 2008;31(12):1115-23 [19026028.001]
  • [Cites] Therapie. 1997 Mar-Apr;52(2):123-7 [9231506.001]
  • [Cites] Indian J Dermatol Venereol Leprol. 2006 Jul-Aug;72(4):286-9 [16880575.001]
  • [Cites] J Am Acad Dermatol. 2007 Apr;56(4):624-8 [17240478.001]
  • [Cites] Ophthalmology. 2008 Dec;115(12):2282-5 [18930555.001]
  • [Cites] Pediatrics. 2005 Nov;116(5):e675-80 [16230465.001]
  • [Cites] Drug Saf. 2006;29(2):143-9 [16454541.001]
  • [Cites] Br J Clin Pharmacol. 2008 Nov;66(5):689-94 [18754840.001]
  • [Cites] Reumatismo. 2005 Jan-Mar;57(1):44-51 [15776146.001]
  • [Cites] Clin Infect Dis. 2006 Jul 15;43(2):e19-22 [16779736.001]
  • [Cites] Drugs Aging. 2004;21(7):479-84 [15132714.001]
  • [Cites] Rev Med Chil. 2006 Jul;134(7):875-82 [17130971.001]
  • [Cites] Ophthalmology. 2006 Feb;113(2):308-14 [16406545.001]
  • [Cites] Ann Dermatol Venereol. 2003 Nov;130(11):1051-5 [14724542.001]
  • (PMID = 21077699.001).
  • [ISSN] 1179-1942
  • [Journal-full-title] Drug safety
  • [ISO-abbreviation] Drug Saf
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  •  go-up   go-down


9. Sipos JA, Mazzaferri EL: The therapeutic management of differentiated thyroid cancer. Expert Opin Pharmacother; 2008 Oct;9(15):2627-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The therapeutic management of differentiated thyroid cancer.
  • BACKGROUND: The management of thyroid cancer is difficult because the tumors comprise a wide range of biologic behaviors, from small papillary thyroid microcarcinomas that pose little or no threat to survival for the patient, to anaplastic thyroid cancers that are arguably the most lethal tumor.
  • Although it may be difficult initially to determine at which end of the prognostic spectrum a patient resides, one can ordinarily estimate a patient's risk for tumor recurrence and mortality based on a triad of features as simple as the patient's age at the time of diagnosis, the tumor stage at presentation, and its initial response to therapy.
  • This is largely because randomized controlled trials are lacking as a result of the low incidence and generally favorable prognosis of the disease.
  • The treatment of these tumors rests on a fine balance of providing care that reflects the anticipated course of the disease without overtreating the patient or providing reassurance that is unfounded.
  • OBJECTIVE: To outline the treatment strategy for patients with differentiated thyroid cancer based on the available literature and to guide clinicians through a management algorithm utilizing patient and tumor characteristics.
  • METHODS: This review is limited to the treatment of patients with differentiated thyroid cancer - papillary and follicular thyroid cancer - and the standard therapy required for the majority of patients.
  • RESULTS/CONCLUSION: The treatment of differentiated thyroid cancer requires a multidisciplinary approach, involving an experienced surgeon, radiologists and an endocrinologist.
  • There are many unanswered questions in the management algorithm and ongoing research is needed to further define the best treatment strategy for patients with differentiated thyroid cancer.
  • [MeSH-major] Thyroid Neoplasms / therapy
  • [MeSH-minor] Cell Differentiation. Combined Modality Therapy. Hormone Replacement Therapy. Humans. Lymph Node Excision. Postoperative Complications. Radiotherapy Dosage. Thyroid Hormones / administration & dosage. Thyroidectomy. Thyrotropin / antagonists & inhibitors

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18803450.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Thyroid Hormones; 9002-71-5 / Thyrotropin
  • [Number-of-references] 102
  •  go-up   go-down


10. Pelosi G, Fumagalli C, Trubia M, Sonzogni A, Rekhtman N, Maisonneuve P, Galetta D, Spaggiari L, Veronesi G, Scarpa A, Malpeli G, Viale G: Dual role of RASSF1 as a tumor suppressor and an oncogene in neuroendocrine tumors of the lung. Anticancer Res; 2010 Oct;30(10):4269-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Twenty typical carcinoids (TC), 11 atypical carcinoids (ATC), 11 large cell neuroendocrine carcinomas (LCNEC) and 16 small cell lung carcinomas (SCLC) were analyzed for RASSF1 promoter methylation, mRNA and protein expression, and loss of 3p21.3 locus.
  • A correlation was found between 3p21.3 allelic loss and decrease of RASSF1 A/E mRNA (p=0.023) and protein (p=0.043) expression in ATC, suggesting that 3p21.3 allelic loss contributed to the loss of gene expression.
  • [MeSH-minor] Adenocarcinoma / genetics. Aged. Carcinoma, Small Cell / genetics. Carcinoma, Squamous Cell / genetics. DNA Methylation. Female. Genes, Tumor Suppressor. Humans. In Situ Hybridization, Fluorescence. Loss of Heterozygosity. Male. Middle Aged. Oncogenes. Promoter Regions, Genetic. RNA, Messenger / biosynthesis. RNA, Messenger / genetics

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21036752.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / RASSF1 protein, human; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


11. Murugan AK, Bojdani E, Xing M: Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochem Biophys Res Commun; 2010 Mar 12;393(3):555-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer.
  • In the present study, we investigated IDH1 and IDH2 mutations in follicular thyroid cancer (FTC) and anaplastic thyroid cancer (ATC), with the latter, like glioblastoma, having a rapidly aggressive and lethal clinical course.
  • By direct genomic DNA sequencing, we analyzed exon 4 of the IDH1 and IDH2 genes that harbored the mutation hot spots codon 132 and 172 of the two genes in glioblastoma, respectively, in 12 thyroid cancer cell lines, 20 FTC, and 18 ATC tumor samples.
  • A novel homozygous G367A IDH1 mutation, resulting in a G123R amino acid change in codon 123, was identified in a case of ATC.
  • A previously described IDH1 V71I mutation was found in a case of FTC and a case of ATC and no mutations were found in the cell lines.
  • The overall prevalence of mutations was thus 1/20 (5%) in FTC and 2/18 (11%) in ATC.
  • We did not find mutation in the IDH2 gene in these thyroid cancer cell lines and tumor samples.
  • Thus, functionally relevant IDH1 mutations can also occur in thyroid cancer, particularly ATC, suggesting a potential tumorigenic role of the IDH1 system that could represent a new therapeutic target for thyroid cancer.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33946-57 [15173171.001]
  • [Cites] N Engl J Med. 2009 Sep 10;361(11):1058-66 [19657110.001]
  • [Cites] Biochemistry. 1997 Nov 4;36(44):13743-7 [9354646.001]
  • [Cites] J Biol Chem. 1999 Oct 22;274(43):30527-33 [10521434.001]
  • [Cites] Int J Oncol. 2008 Jan;32(1):101-11 [18097548.001]
  • [Cites] Endocrinol Metab Clin North Am. 2008 Jun;37(2):525-38, xi [18502341.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Acta Neuropathol. 2008 Dec;116(6):597-602 [18985363.001]
  • [Cites] Hum Mutat. 2009 Jan;30(1):7-11 [19117336.001]
  • [Cites] N Engl J Med. 2009 Feb 19;360(8):765-73 [19228619.001]
  • [Cites] Science. 2009 Apr 10;324(5924):261-5 [19359588.001]
  • [Cites] Int J Cancer. 2009 Jul 15;125(2):353-5 [19378339.001]
  • [Cites] Cell Cycle. 2009 Jul 1;8(13):2122-4 [19411838.001]
  • [Cites] Neuro Oncol. 2009 Aug;11(4):341-7 [19435942.001]
  • [Cites] Arch Microbiol. 1997 Nov;168(5):412-20 [9325430.001]
  • (PMID = 20171178.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA134225-01A2; United States / NCI NIH HHS / CA / R01 CA113507; United States / NCI NIH HHS / CA / CA134225-01A2; United States / NCI NIH HHS / CA / R01CA134225-01; United States / NCI NIH HHS / CA / R01 CA134225
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.42. / IDH1 protein, human
  • [Other-IDs] NLM/ NIHMS182112; NLM/ PMC2838977
  •  go-up   go-down


12. Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Filipenko D, Huntsman D, Gilks B: Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. Am J Surg; 2006 May;191(5):581-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma.
  • BACKGROUND: Anaplastic thyroid cancer arises, or transforms, from pre-existing differentiated thyroid cancer.
  • The objective of this study was to evaluate the change in E-cadherin/beta-catenin expression in the transformation of differentiated to anaplastic thyroid carcinoma.
  • METHODS: A tissue microarray was constructed from 12 anaplastic thyroid tumors and their adjacent associated differentiated foci.
  • RESULTS: There was decreased expression of E-cadherin and beta-catenin by the anaplastic tumors when compared with the differentiated thyroid tumors from which they evolved.
  • The expression of E-cadherin and beta-catenin was 92% and 67%, respectively, by the differentiated thyroid carcinoma, and 17% and 50%, respectively, by the anaplastic tumors.
  • CONCLUSIONS: This report shows that derangement of the E-cadherin/catenin complex is associated with the transformation of differentiated into anaplastic thyroid carcinoma.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Carcinoma / metabolism. Catenins / biosynthesis. Cell Transformation, Neoplastic / metabolism. Thyroid Neoplasms / metabolism. beta Catenin / biosynthesis
  • [MeSH-minor] Aged. Aged, 80 and over. Anaplasia. Disease Progression. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16647341.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Catenins; 0 / beta Catenin
  •  go-up   go-down


13. Libertini S, Iacuzzo I, Ferraro A, Vitale M, Bifulco M, Fusco A, Portella G: Lovastatin enhances the replication of the oncolytic adenovirus dl1520 and its antineoplastic activity against anaplastic thyroid carcinoma cells. Endocrinology; 2007 Nov;148(11):5186-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lovastatin enhances the replication of the oncolytic adenovirus dl1520 and its antineoplastic activity against anaplastic thyroid carcinoma cells.
  • Anaplastic thyroid carcinoma (ATC) is one of the most aggressive solid tumors and shows morphological features of a highly malignant, undifferentiated neoplasm.
  • Patients with ATC have a poor prognosis with a mean survival time of 2-6 months; surgery, radiotherapy, and chemotherapy do not improve survival.
  • Gene therapy approaches and oncolytic viruses have been tested for the treatment of ATC.
  • To enhance the antineoplastic effects of the oncolytic adenovirus dl1520 (Onyx-015), we treated ATC cells with lovastatin (3-hydroxy-methylglutaryl-CoA reductase inhibitor), a drug used for the treatment of hypercholesterolemia, which has previously been reported to exert growth-inhibitory and apoptotic activity on ATC cells.
  • Lovastatin treatment significantly increased the effects of dl1520 against ATC cells.
  • The replication of dl1520 in ATC cells was enhanced by lovastatin treatment, and a significant increase of the expression of the early gene E1A 13 S and the late gene Penton was observed in lovastatin-treated cells.
  • Furthermore, lovastatin treatment significantly enhanced the effects of dl1520 against ATC tumor xenografts.
  • Lovastatin treatment could be exploited to increase the efficacy of oncolytic adenoviruses, and further studies are warranted to confirm the feasibility of the approach in ATC patients.
  • [MeSH-major] Adenoviridae / drug effects. Antineoplastic Agents / therapeutic use. Carcinoma / therapy. Lovastatin / pharmacology. Lovastatin / therapeutic use. Oncolytic Virotherapy. Thyroid Neoplasms / therapy. Virus Replication / drug effects

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. LOVASTATIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17690162.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / ONYX015; 0 / Viral Vaccines; 9LHU78OQFD / Lovastatin
  •  go-up   go-down


14. Hoffmann S, Maschuw K, Hassan I, Reckzeh B, Wunderlich A, Lingelbach S, Zielke A: Differential pattern of integrin receptor expression in differentiated and anaplastic thyroid cancer cell lines. Thyroid; 2005 Sep;15(9):1011-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential pattern of integrin receptor expression in differentiated and anaplastic thyroid cancer cell lines.
  • Adhesion of tumor cells to the extracellular matrix (ECM) is a crucial step for the development of metastatic disease and is mediated by specific integrin receptor molecules (IRM).
  • The pattern of metastatic spread differs substantially among the various histotypes of thyroid cancer (TC).
  • IRM expression was investigated in 10 differentiated (FTC133, 236, 238, HTC, HTC TSHr, XTC, PTC4.0/4.2, TPC1, Kat5) and two anaplastic TC cell lines (ATC, C643, Hth74), primary cultures of normal thyroid tissue (Thy1,3), and thyroid cancer specimens (TCS).
  • Thyroid tumor cell adhesion to ECM proteins and their IRM expression in response to thyrotropin (TSH) was assessed.
  • ATC mainly displayed integrins alpha2, alpha3, alpha5, alpha6, beta1 and low levels of alpha1, alpha4 and alphaV.
  • Thyroid carcinoma cell lines of different histogenetic background display profoundly different patterns of IRM expression that appear to correlate with tumor aggressiveness.
  • Finally, TSH-stimulated adhesion of thyroid tumor cell lines to ECM may not be associated with altered IRM expression.
  • [MeSH-major] Carcinoma / genetics. Integrins / biosynthesis. Integrins / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Cell Adhesion. Cell Differentiation / drug effects. Cell Differentiation / genetics. Cell Line, Tumor. Extracellular Matrix Proteins / metabolism. Flow Cytometry. Humans. Paraffin Embedding. Stimulation, Chemical. Thyrotropin / pharmacology


15. Cox S, Southby J: Apricitabine--a novel nucleoside reverse transcriptase inhibitor for the treatment of HIV infection that is refractory to existing drugs. Expert Opin Investig Drugs; 2009 Feb;18(2):199-209
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Apricitabine (ATC) is a nucleoside reverse transcriptase inhibitor (NRTI) being developed for the treatment of HIV.
  • ATC has promising antiviral activity, including against HIV-1 containing reverse transcriptase mutations that confer resistance to other NRTIs.
  • OBJECTIVES: This paper describes the development of ATC, including its in vitro activity, pharmacokinetics and clinical efficacy and safety.
  • METHODS: The current literature on ATC was reviewed.
  • RESULTS/CONCLUSIONS: ATC is a novel deoxycytidine NRTI with good antiviral activity, both in vitro and in treatment-naïve and treatment-experienced HIV-1-infected patients, including those with resistance to other NRTIs.
  • ATC may have a place in the treatment of patients who have failed previous treatment regimens due to the development of NRTI resistance as a replacement for existing drugs.
  • [MeSH-major] Anti-HIV Agents / therapeutic use. Deoxycytidine / analogs & derivatives. HIV Infections / drug therapy. Reverse Transcriptase Inhibitors / therapeutic use

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19236266.001).
  • [ISSN] 1744-7658
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Reverse Transcriptase Inhibitors; 0W860991D6 / Deoxycytidine; K1YX059ML1 / apricitabine
  • [Number-of-references] 47
  •  go-up   go-down


16. O'Neill JP, Power D, Condron C, Bouchier-Hayes D, Walsh M: Anaplastic thyroid cancer, tumorigenesis and therapy. Ir J Med Sci; 2010 Mar;179(1):9-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic thyroid cancer, tumorigenesis and therapy.
  • BACKGROUND: Anaplastic thyroid cancer (ATC) is a fatal endocrine malignancy.
  • Recent insights into thyroid tumorigenesis, post-malignant dedifferentiation and mode of metastatic activity offer new therapeutic strategies.
  • METHODS: An extensive literature search of Medline and Pubmed was conducted to include all published reports on ATC.
  • CONCLUSIONS: Significant progress, in the last 5 years, has been made outlining thyroid tumorigenesis and the progression to anaplasia.
  • [MeSH-major] Thyroid Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cadherins. Cyclins. Disease Progression. Humans. Radiotherapy. Receptor, Epidermal Growth Factor. Vascular Endothelial Growth Factor A. beta Catenin

  • Genetic Alliance. consumer health - Thyroid cancer, anaplastic.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2003 Jun;42(6):580-7 [12786894.001]
  • [Cites] Int J Cancer. 2006 Jul 15;119(2):275-82 [16477625.001]
  • [Cites] Am J Surg. 2006 May;191(5):581-7 [16647341.001]
  • [Cites] Head Neck. 2003 Aug;25(8):662-70 [12884350.001]
  • [Cites] Head Neck. 2007 Aug;29(8):765-72 [17274052.001]
  • [Cites] J Cell Physiol. 2006 Dec;209(3):686-94 [17001684.001]
  • [Cites] Growth Factors. 2006 Mar;24(1):13-9 [16393691.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1161-70 [17317825.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12 (2):600-7 [16428506.001]
  • [Cites] Cancer Sci. 2007 Sep;98(9):1303-10 [17608770.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):987-96 [11238046.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):928-35 [15562011.001]
  • [Cites] Endocrine. 2007 Apr;31(2):105-13 [17873319.001]
  • [Cites] Ann Surg. 2000 Mar;231(3):329-38 [10714625.001]
  • [Cites] Surgery. 2006 Dec;140(6):899-905; discussion 905-6 [17188136.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10199-207 [16288007.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):453-64 [16474910.001]
  • [Cites] Anticancer Res. 2007 Jul-Aug;27(4B):2515-22 [17695547.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3716-25 [15867367.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jan;87(1):370-9 [11788678.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Sep;131(9):585-90 [16021466.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):719-29 [17115102.001]
  • [Cites] Eur J Endocrinol. 2007 Apr;156(4):425-30 [17389456.001]
  • [Cites] Oncogene. 1989 Feb;4(2):159-64 [2648253.001]
  • [Cites] Thyroid. 2004 Nov;14 (11):889-95 [15671766.001]
  • [Cites] Cancer. 2005 Jun 1;103(11):2261-8 [15880523.001]
  • [Cites] World J Surg. 2001 May;25(5):617-22 [11369989.001]
  • [Cites] World J Surg. 2007 May;31(5):969-77 [17483987.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Mar;87(3):1247-53 [11889195.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1330-5 [15739211.001]
  • [Cites] Surg Oncol. 2003 Aug;12(2):69-90 [12946479.001]
  • [Cites] BMC Cancer. 2005 Jul 19;5:80 [16029487.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):671-7 [10934169.001]
  • [Cites] Hum Pathol. 2007 Apr;38(4):621-8 [17270245.001]
  • [Cites] Cancer Lett. 1995 Aug 16;95(1-2):135-8 [7656221.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jan;85(1):302-8 [10634403.001]
  • [Cites] Eur J Cancer. 2002 Aug;38(12):1661-70 [12142058.001]
  • [Cites] J Clin Invest. 1993 Jan;91(1):179-84 [8423216.001]
  • [Cites] Thyroid. 1998 Aug;8(8):715-26 [9737368.001]
  • [Cites] Ann N Y Acad Sci. 2004 Dec;1030:69-77 [15659782.001]
  • [Cites] Nucl Med Biol. 2006 Oct;33(7):875-82 [17045167.001]
  • [Cites] Oncogene. 1995 Oct 19;11(8):1569-79 [7478581.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):57-64 [11833496.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5399-404 [14602780.001]
  • [Cites] Endocr Pathol. 2007 Spring;18(1):1-7 [17652794.001]
  • [Cites] J Surg Oncol. 2006 Dec 15;94(8):662-9 [17131411.001]
  • [Cites] Mol Cancer Ther. 2005 Apr;4(4):632-40 [15827337.001]
  • [Cites] Head Neck. 1996 Jan-Feb;18(1):36-41 [8774920.001]
  • [Cites] Laryngoscope. 2007 Apr;117(4):674-9 [17429874.001]
  • [Cites] Mol Cancer Ther. 2007 Jun;6(6):1785-92 [17575107.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1811-5 [10213482.001]
  • [Cites] Curr Biol. 2002 Jul 9;12(13):R458-60 [12121637.001]
  • [Cites] Arch Surg. 2007 Aug;142(8):717-27; discussion 727-9 [17709725.001]
  • [Cites] Oncol Rep. 2002 Sep-Oct;9(5):915-28 [12168049.001]
  • (PMID = 19662494.001).
  • [ISSN] 1863-4362
  • [Journal-full-title] Irish journal of medical science
  • [ISO-abbreviation] Ir J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cadherins; 0 / Cyclins; 0 / Vascular Endothelial Growth Factor A; 0 / beta Catenin; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 54
  •  go-up   go-down


17. Maegele M: Acute traumatic coagulopathy: Incidence, risk stratification and therapeutic options. World J Emerg Med; 2010;1(1):12-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute traumatic coagulopathy: Incidence, risk stratification and therapeutic options.
  • A synopsis is presented of different retrospective analyses based upon datasets from severe multiply injured patients derived from the TR-DGU database (Trauma Registry of the Deutsche Gesellschaft fur Unfallchirurgie (DGU)/ German Society of Trauma Surgery) with respect to frequency, risk stratification and therapeutic options of acute traumatic coagulopathy (ATC).
  • METHODS: The synopsis of different analyses based upon the datasets from severe multiply injured patients derived from the TR-DGU database and development/validation of a scoring system (TASH-score = Trauma Associated Severe Hemorrhage) that allows an early and reliable estimation for the probability of massive transfusion as a surrogate for life-threatening hemorrhage after severe multiple injuries.
  • RESULTS: The high frequency of ATC upon emergency room admission is associated with significant morbidity and mortality in multiply injured patients.
  • The TASH-score is recognized as an easy-to-calculate and valid scoring system to predict the individual's probability for massive transfusion and thus ongoing life-threatening hemorrhage at a very early stage after severe multiple injuries.
  • CONCLUSION: An early aggressive management of ATC including a more balanced administration of blood products to improve outcome is advocated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25214935.001).
  • [ISSN] 1920-8642
  • [Journal-full-title] World journal of emergency medicine
  • [ISO-abbreviation] World J Emerg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4129771
  • [Keywords] NOTNLM ; Coagulopathy / Epidemiology / Management / Risk stratification / Trauma
  •  go-up   go-down


18. Metz-Gercek S, Maieron A, Strauss R, Wieninger P, Apfalter P, Mittermayer H: Ten years of antibiotic consumption in ambulatory care: trends in prescribing practice and antibiotic resistance in Austria. BMC Infect Dis; 2009;9:61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The primary aims of this study were (i) to determine the quantity and pattern of antibiotic use in Austria between 1998 and 2007 and (ii) to analyze antibiotic esistance rates in relation to antibiotic consumption in important clinical situations in order to provide data for empirical therapeutic regimens for key indications.
  • METHODS: Consumption data and resistance data were obtained via the Austrian surveillance networks European Antimicrobial Resistance Surveillance System (EARSS) and European Surveillance on Antimicrobial Consumption (ESAC).
  • The Anatomical Therapeutic Chemical (ATC) classification and the Defined Daily Dose (DDD) measurement units were assigned to the data.
  • The percentage of nonsusceptible or intermediate penicillin-resistant pneumococcal isolates remained stable over this time period at around 5%.
  • [MeSH-major] Ambulatory Care / trends. Anti-Bacterial Agents / therapeutic use. Drug Resistance, Bacterial. Practice Patterns, Physicians' / trends. Prescriptions / statistics & numerical data

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Antibiotic Resistance.
  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Microbiol Infect. 2000 Feb;6(2):59-63 [11168073.001]
  • [Cites] Clin Microbiol Infect. 2008 Jan;14 Suppl 1:104-10 [18154533.001]
  • [Cites] Lancet. 2003 Dec 13;362(9400):1991-2001 [14683661.001]
  • [Cites] Lancet. 2005 Feb 12-18;365(9459):579-87 [15708101.001]
  • [Cites] J Antimicrob Chemother. 2006 Aug;58(2):401-7 [16735414.001]
  • [Cites] J Antimicrob Chemother. 2006 Aug;58(2):408-12 [16735415.001]
  • [Cites] J Antimicrob Chemother. 2006 Aug;58(2):413-7 [16735416.001]
  • [Cites] J Antimicrob Chemother. 2006 Aug;58(2):423-7 [16735418.001]
  • [Cites] Jpn J Infect Dis. 2006 Oct;59(5):299-05 [17060695.001]
  • [Cites] Urology. 2006 Dec;68(6):1169-74 [17169640.001]
  • [Cites] Clin Infect Dis. 2007 Apr 15;44(8):1091-5 [17366456.001]
  • [Cites] Am J Health Syst Pharm. 2007 Dec 1;64(23 Suppl 14):S3-21; quiz S22-4 [18029939.001]
  • [Cites] Med J Aust. 2008 Feb 18;188(4):209-13 [18279126.001]
  • [Cites] BMC Infect Dis. 2008;8:71 [18501015.001]
  • [Cites] J Infect. 2008 Sep;57(3):179-84 [18707763.001]
  • [Cites] Clin Infect Dis. 2008 Nov 1;47(9):1150-8 [18808361.001]
  • [Cites] Clin Infect Dis. 2001 Apr 15;32(8):1162-71 [11283805.001]
  • (PMID = 19439064.001).
  • [ISSN] 1471-2334
  • [Journal-full-title] BMC infectious diseases
  • [ISO-abbreviation] BMC Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  • [Other-IDs] NLM/ PMC2686702
  •  go-up   go-down


19. Swartz EE, Belmore K, Decoster LC, Armstrong CW: Emergency face-mask removal effectiveness: a comparison of traditional and nontraditional football helmet face-mask attachment systems. J Athl Train; 2010 Nov-Dec;45(6):560-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PARTICIPANTS: Twenty-five certified athletic trainers.
  • INTERVENTION(S): The independent variable was face-mask attachment system on 5 levels:.
  • [MeSH-major] Athletic Injuries / epidemiology. Facial Injuries / epidemiology. Football / injuries. Head Protective Devices. Spinal Cord Injuries / epidemiology. Sports Medicine


20. Chen SN, Xue YQ, Zhang XG, Wu YF, Pan JL, Wang Y, Cen JN: [Establishment and characterization of a human acute monocytic leukemic cell line, SHI-1, carrying t(6;11)(q27;23) and p53 gene alteration]. Zhonghua Xue Ye Xue Za Zhi; 2005 Feb;26(2):94-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Mononuclear cells isolated from the bone marrow of an acute monocytic leukemia (AML-M(5b)) patient at relapse were inoculated in a liquid culture system.
  • The cell line presented typical morphology and immuno-profile of monocytic lineage with the original t(6;11)(q27;q23) and del(17)(p11) abnormalities.
  • A point mutation of ATC-->ACC at exon 6 of the p53 gene was found by sequencing of the PCR products.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15921626.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


21. Ricciardelli L, Rapicano G, Pinto A, Napolitano G, Feleppa C, Martino G, Martino A: [Small bowel intussusception caused by metastasis from anaplastic thyroid carcinoma: case report and literature review]. Ann Ital Chir; 2006 Jan-Feb;77(1):63-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Small bowel intussusception caused by metastasis from anaplastic thyroid carcinoma: case report and literature review].
  • [Transliterated title] Invaginazione ileo-ileale da metastasi di carcinoma anaplastico tiroideo. Caso clinico e revisione della letteratura.
  • Symptomatic involvement of the small bowel by metastasis from an extra-abdominal primary malignancy is rare, most commonly resulting from malignant melanoma and lung cancer; very rarely is small bowel involvement as first metastatic site.
  • The Authors report a case of anaplastic thyroid carcinoma with lung metastasis, brain metastasis and an isolated metastasis to the small bowel leading intestinal obstruction due to small bowel intussusception.
  • The Authors review the international literature about frequency, etiopathogenesis, clinical and diagnostic features and therapy of small bowel metastasis by extra-abdominal malignancies, especially by primary anaplastic thyroid carcinoma.
  • Small bowel metastasis from extra-abdominal malignancies are very unusual, especially from anaplastic thyroid carcinoma, and the etiopathogenesis is still unknown.
  • Clinical findings are typical for abdominal urgency, especially by small bowel obstruction from anaplastic thyroid carcinoma.
  • [MeSH-major] Carcinoma / complications. Carcinoma / diagnosis. Ileal Neoplasms / complications. Ileal Neoplasms / diagnosis. Intussusception / etiology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16910363.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 37
  •  go-up   go-down


22. Presta I, Arturi F, Ferretti E, Mattei T, Scarpelli D, Tosi E, Scipioni A, Celano M, Gulino A, Filetti S, Russo D: Recovery of NIS expression in thyroid cancer cells by overexpression of Pax8 gene. BMC Cancer; 2005;5:80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recovery of NIS expression in thyroid cancer cells by overexpression of Pax8 gene.
  • BACKGROUND: Recovery of iodide uptake in thyroid cancer cells by means of obtaining the functional expression of the sodium/iodide symporter (NIS) represents an innovative strategy for the treatment of poorly differentiated thyroid cancer.
  • METHODS: In this study, the anaplastic thyroid carcinoma ARO cells were stably transfected with a Pax8 gene expression vector.
  • A quantitative RT-PCR was performed to assess the thyroid specific gene expression in selected clones.
  • RESULTS: The clones overexpressing Pax8 showed the re-activation of several thyroid specific genes including NIS, Pendrin, Thyroglobulin, TPO and TTF1.
  • CONCLUSION: These finding demonstrate that induction of Pax8 expression may determine a re-differentiation of thyroid cancer cells, including a partial recovery of iodide uptake, fundamental requisite for a radioiodine-based therapeutic approach for thyroid tumours.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Paired Box Transcription Factors / biosynthesis. Symporters / biosynthesis. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Cell Proliferation. Cytoplasm / metabolism. DNA Primers / chemistry. Genetic Vectors. Humans. Iodides / metabolism. Iodine Radioisotopes / metabolism. Membrane Transport Proteins / biosynthesis. Microscopy, Fluorescence. Plasmids / metabolism. RNA / chemistry. RNA, Messenger / metabolism. Recombinant Proteins / chemistry. Reverse Transcriptase Polymerase Chain Reaction. Thymus Gland / metabolism. Thyroglobulin / biosynthesis. Transcription, Genetic. Transfection

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocrinology. 2004 Mar;145(3):1290-3 [14630715.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):1006-9 [14764827.001]
  • [Cites] Endocrinology. 2004 Jun;145(6):2865-75 [14976143.001]
  • [Cites] Endocrinology. 2004 Nov;145(11):5397-405 [15271884.001]
  • [Cites] Endocrinology. 1984 Apr;114(4):1090-8 [6705729.001]
  • [Cites] J Clin Endocrinol Metab. 1986 Oct;63(4):960-7 [3745409.001]
  • [Cites] Endocrinology. 1989 Oct;125(4):1783-8 [2551628.001]
  • [Cites] Development. 1990 Oct;110(2):643-51 [1723950.001]
  • [Cites] Mol Cell Biol. 1992 Sep;12(9):4230-41 [1508216.001]
  • [Cites] EMBO J. 1994 Jul 15;13(14):3339-47 [7913891.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4744-9 [8062273.001]
  • [Cites] N Engl J Med. 1996 Jan 4;334(1):28-33 [7494569.001]
  • [Cites] Nature. 1996 Feb 1;379(6564):458-60 [8559252.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Nov 26;240(3):832-8 [9398654.001]
  • [Cites] N Engl J Med. 1998 Jan 29;338(5):297-306 [9445411.001]
  • [Cites] Surgery. 1998 Dec;124(6):1100-5 [9854590.001]
  • [Cites] Eur J Endocrinol. 1998 Dec;139(6):563-6 [9916856.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Jul;84(7):2449-57 [10404820.001]
  • [Cites] Eur J Endocrinol. 1999 Nov;141(5):443-57 [10576759.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 2001;66:307-56 [11051768.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13144-9 [11069301.001]
  • [Cites] Thyroid. 2001 May;11(5):415-25 [11396700.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jul;86(7):3327-35 [11443208.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jul;86(7):3430-5 [11443220.001]
  • [Cites] Eur J Endocrinol. 2001 Aug;145(2):129-35 [11454507.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2001;109(1):27-31 [11573135.001]
  • [Cites] Eur J Endocrinol. 2001 Nov;145(5):591-7 [11720877.001]
  • [Cites] Endocrinology. 2002 Jun;143(6):2216-20 [12021185.001]
  • [Cites] Mol Endocrinol. 2002 Oct;16(10):2266-82 [12351692.001]
  • [Cites] Surgery. 2002 Dec;132(6):984-90; discussion 990 [12490845.001]
  • [Cites] Lancet. 2003 Feb 8;361(9356):501-11 [12583960.001]
  • [Cites] Endocr Rev. 2003 Feb;24(1):48-77 [12588808.001]
  • [Cites] Nucleic Acids Res. 2003 Apr 1;31(7):1845-52 [12655000.001]
  • [Cites] Eur J Endocrinol. 2003 Apr;148(4):395-402 [12656659.001]
  • [Cites] Oncol Rep. 2003 Jul-Aug;10(4):845-9 [12792733.001]
  • [Cites] Mol Cell Endocrinol. 2004 Feb 12;214(1-2):117-25 [15062550.001]
  • (PMID = 16029487.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Iodides; 0 / Iodine Radioisotopes; 0 / Membrane Transport Proteins; 0 / PAX8 protein, human; 0 / Paired Box Transcription Factors; 0 / RNA, Messenger; 0 / Recombinant Proteins; 0 / SLC26A4 protein, human; 0 / Symporters; 0 / sodium-iodide symporter; 63231-63-0 / RNA; 9010-34-8 / Thyroglobulin
  • [Other-IDs] NLM/ PMC1180821
  •  go-up   go-down


23. Zhang W, Shen X, Wang Y, Chen Y, Huang M, Zeng Q, Wei J, Lu Q, Wang G, Deng L, Wang X, Yao K, Yu S, Yang Y: Antibiotic use in five children's hospitals during 2002-2006: the impact of antibiotic guidelines issued by the Chinese Ministry of Health. Pharmacoepidemiol Drug Saf; 2008 Mar;17(3):306-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The Anatomical Therapeutic Chemical Classification/Defined Daily Doses (ATC/DDD) methodology was used.
  • Aggregate data on antibiotic use (ATC code-J01) were expressed in numbers of DDD/100 bed-days for inpatients.
  • CONCLUSIONS: The ATC/DDD methodology proved useful for studying overall antibiotic usage in children's hospitals.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Drug Utilization / statistics & numerical data. Guideline Adherence / statistics & numerical data. Hospitals, Pediatric / statistics & numerical data
  • [MeSH-minor] Adolescent. Cephalosporins / therapeutic use. Child. Child, Preschool. China. Databases, Factual. Female. Humans. Infant. Male. Practice Guidelines as Topic. Practice Patterns, Physicians' / statistics & numerical data. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 John Wiley & Sons, Ltd.
  • (PMID = 18165944.001).
  • [ISSN] 1099-1557
  • [Journal-full-title] Pharmacoepidemiology and drug safety
  • [ISO-abbreviation] Pharmacoepidemiol Drug Saf
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Cephalosporins
  •  go-up   go-down


24. Vanatta LE, Woodruff A, Coleman DE: Comparison of two cryptand separator columns for the determination of trace chloride in semiconductor-grade nitric acid. J Chromatogr A; 2005 Aug 26;1085(1):33-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Also, the use of a Continuously Regenerated Anion Trap Column (CR-ATC) was evaluated for its ability to purify electrolytically generated eluent.
  • Results also showed that the CR-ATC was necessary for obtaining acceptable acid blanks.

  • Hazardous Substances Data Bank. NITRIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16106844.001).
  • [ISSN] 0021-9673
  • [Journal-full-title] Journal of chromatography. A
  • [ISO-abbreviation] J Chromatogr A
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anion Exchange Resins; 0 / Bicyclo Compounds, Heterocyclic; 0 / Chlorides; 23978-09-8 / cryptating agent 222; 31364-42-8 / cryptating agent 221; 411VRN1TV4 / Nitric Acid
  •  go-up   go-down


25. Nonaka D, Tang Y, Chiriboga L, Rivera M, Ghossein R: Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms. Mod Pathol; 2008 Feb;21(2):192-200
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms.
  • Thyroid-specific transcription factors, Pax8, TTF-1, and TTF-2, are crucial for thyroid organogenesis and differentiation.
  • The goal of this study is to evaluate the expressions of these markers in thyroid tumors of the full spectrum of differentiation, with special emphasis on anaplastic carcinomas.
  • A total of 94 cases of thyroid neoplasms were studied: 17 papillary carcinomas, 18 follicular adenomas, 16 follicular carcinomas, 7 poorly differentiated carcinomas, 28 anaplastic carcinomas, and 8 medullary carcinomas.
  • The antibodies to Pax8 and TTF-2 were also applied on 147 lung carcinomas as well as a variety of normal tissues and malignant tumors.
  • All three markers were seen in papillary carcinomas, follicular adenomas and carcinomas, and poorly differentiated carcinomas in a diffuse manner, whereas their expressions in medullary carcinomas were variable.
  • Pax8 was expressed in 79% of anaplastic carcinomas to a variable extent, whereas TTF-1 and TTF-2 were seen only in 18 and 7% of anaplastic carcinomas, respectively.
  • Pax8 was expressed in renal tubules, fallopian tubes, ovarian inclusion cysts, and lymphoid follicles as well as renal carcinoma, nephroblastoma, seminoma, and ovarian carcinoma, but not in normal tissue and carcinomas of the lung.
  • Pax8 is a useful marker for the diagnosis of anaplastic carcinomas, particularly when the differential diagnosis includes pulmonary carcinoma.
  • In differentiated thyroid neoplasms, no significant difference in expression was seen in all the three transcription factors.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Adenosine Triphosphatases / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Papillary / metabolism. DNA-Binding Proteins / metabolism. Paired Box Transcription Factors / metabolism. Thyroid Neoplasms / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / metabolism. Adolescent. Adult. Aged. Aged, 80 and over. Calcitonin / metabolism. Carcinoma / diagnosis. Carcinoma / metabolism. Carcinoma, Medullary / diagnosis. Carcinoma, Medullary / metabolism. Female. Fluorescent Antibody Technique, Indirect. Humans. Hyperplasia. Immunoenzyme Techniques. Male. Middle Aged. Thyroid Gland / metabolism. Thyroid Gland / pathology. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Calcitonin .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18084247.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / PAX8 protein, human; 0 / Paired Box Transcription Factors; 0 / Transcription Factors; 9007-12-9 / Calcitonin; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.1.- / TTF2 protein, human
  •  go-up   go-down


26. Cohen JD, Shapiro M, Grozovski E, Lev S, Fisher H, Singer P: Extubation outcome following a spontaneous breathing trial with automatic tube compensation versus continuous positive airway pressure. Crit Care Med; 2006 Mar;34(3):682-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extubation outcome following a spontaneous breathing trial with automatic tube compensation versus continuous positive airway pressure.
  • OBJECTIVE: We hypothesized that the additional use of automatic tube compensation (ATC) during a spontaneous breathing trial with continuous positive airway pressure (CPAP), by minimizing respiratory work, would result in more patients undergoing successful extubation.
  • INTERVENTIONS: Patients were randomized to undergo a 1-hr spontaneous breathing trial with either ATC with CPAP (ATC group, n=51) or CPAP alone (CPAP group, n=48).
  • ATC was provided by commercially available mechanical ventilators.
  • There was a trend for more patients in the ATC group to tolerate the breathing trial and undergo extubation (96% vs. 85%; p=.08).
  • The rate of reintubation was 14% in the ATC group and 24% in the CPAP group (p=.28).
  • Significantly more patients in the ATC group thus met the criteria for successful extubation (82% vs. 65%; p=0.04).
  • CONCLUSION: This is the largest single-center study to date assessing the use of commercially available ATC and suggests that this might be a useful mode for performing a spontaneous breathing trial preceding extubation in a general intensive care population.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Crit Care Med. 2006 Nov;34(11):2867; author reply 2867 [17053584.001]
  • (PMID = 16505653.001).
  • [ISSN] 0090-3493
  • [Journal-full-title] Critical care medicine
  • [ISO-abbreviation] Crit. Care Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


27. Yamai H, Yoshida T, Toba H, Kira M, Takizawa H, Tangoku A: [A case of anaplastic carcinoma of thyroid administered peroral fluorinated pyrimidine for long-term survival during three years]. Gan To Kagaku Ryoho; 2009 Jun;36(6):1021-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of anaplastic carcinoma of thyroid administered peroral fluorinated pyrimidine for long-term survival during three years].
  • We report a case of anaplastic carcinoma of the thyroid administered peroral fluorinated pyrimidine, providing longterm survival during three years.
  • Three years ago, a 70-year-old woman diagnosed with anaplastic carcinoma of the thyroid was admitted for chemoradiation therapy after tumor resection and tracheostomy.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma / drug therapy. Oxonic Acid / administration & dosage. Tegafur / administration & dosage. Thyroid Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542729.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 5VT6420TIG / Oxonic Acid; 1-UFT protocol
  •  go-up   go-down


28. Hermes M, Schormann W, Brulport M, Uhlemann K, Lupatsch F, Horn LC, Schumann A, Allgaier C, Weishaupt M, Engeland K, Müller GA, Mössner J, Bauer A, Schiffer IB, Gebhard S, Schmidt M, Lausch E, Prawitt D, Wilhelm C, Hengstler JG: Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model. Br J Cancer; 2008 May 6;98(9):1525-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Trastuzumab (Herceptin) has improved therapy of breast cancer.
  • We used a mouse model that allows anhydrotetracycline (ATc)-controlled downregulation of ERBB2 in tumour tissue.
  • Surprisingly, trastuzumab caused a much weaker effect compared to ATc-induced ERBB2 downregulation, although a decrease in ERBB2 membrane localisation was induced.
  • The suboptimal effect of trastuzumab compared to the maximally possible effect induced by ATc demonstrates a high potential for improved ERBB2 blocking therapies.

  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2639-48 [10561337.001]
  • [Cites] Curr Cancer Drug Targets. 2006 Nov;6(7):603-12 [17100566.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4744-9 [11406546.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):719-26 [11821453.001]
  • [Cites] Science. 2002 Jul 5;297(5578):63-4 [12098689.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):4132-41 [12124352.001]
  • [Cites] Mol Cancer Ther. 2002 Jul;1(9):707-17 [12479367.001]
  • [Cites] Nature. 2003 Feb 13;421(6924):756-60 [12610629.001]
  • [Cites] Curr Opin Chem Biol. 2003 Aug;7(4):490-5 [12941424.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7221-31 [14612517.001]
  • [Cites] Mol Cell Biol. 1989 Mar;9(3):1165-72 [2566907.001]
  • [Cites] Cancer Res. 1990 Mar 1;50(5):1550-8 [1689212.001]
  • [Cites] Cell. 1990 Apr 20;61(2):203-12 [2158859.001]
  • [Cites] J Biol Chem. 1991 Aug 5;266(22):14300-5 [1677643.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5547-51 [1319065.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):737-44 [8622019.001]
  • [Cites] Oncogene. 1996 Sep 5;13(5):901-11 [8806679.001]
  • [Cites] J Drug Target. 2004;12(7):461-71 [15621671.001]
  • [Cites] Clin Breast Cancer. 2005 Aug;6(3):240-6 [16137435.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1659-72 [16236737.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1673-84 [16236738.001]
  • [Cites] Mol Carcinog. 2006 May;45(5):302-8 [16496387.001]
  • [Cites] Science. 2006 May 26;312(5777):1175-8 [16728632.001]
  • [Cites] N Engl J Med. 2006 Jun 15;354(24):2619-21 [16775247.001]
  • [Cites] Curr Cancer Drug Targets. 2006 Jun;6(4):333-63 [16848724.001]
  • [Cites] Int J Clin Oncol. 2006 Jun;11(3):199-208 [16850126.001]
  • [Cites] J Clin Oncol. 2006 Aug 10;24(23):3735-46 [16847284.001]
  • [Cites] Breast Cancer. 2006;13(3):236-48 [16929116.001]
  • [Cites] Mol Pharmacol. 2006 Nov;70(5):1534-41 [16887935.001]
  • [Cites] Nat Med. 2000 Apr;6(4):443-6 [10742152.001]
  • (PMID = 18454161.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Ki-67 Antigen; 0 / RNA, Messenger; 0 / Tetracyclines; 680VDL31MX / 4-epianhydrotetracycline; 9007-43-6 / Cytochromes c; EC 2.7.10.1 / Erbb2 protein, mouse; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.11.1 / 3-Phosphoinositide-Dependent Protein Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; P188ANX8CK / Trastuzumab
  • [Other-IDs] NLM/ PMC2391101
  •  go-up   go-down


29. Yard EE, Schroeder MJ, Fields SK, Collins CL, Comstock RD: The epidemiology of United States high school soccer injuries, 2005-2007. Am J Sports Med; 2008 Oct;36(10):1930-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Soccer-related injury data were collected over the 2005-2006 and 2006-2007 school years from 100 nationally representative United States high schools via Reporting Information Online (RIO, an Internet-based sports-related injury surveillance system).
  • RESULTS: Participating certified athletic trainers reported 1524 soccer injuries during 637 446 athlete exposures (AEs), for an injury rate of 2.39 per 1000 AEs, corresponding to a nationally estimated 807 492 soccer-related injuries during the 2005-2006 and 2006-2007 seasons.
  • [MeSH-major] Athletic Injuries / epidemiology. Soccer / injuries

  • MedlinePlus Health Information. consumer health - Sports Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18628486.001).
  • [ISSN] 1552-3365
  • [Journal-full-title] The American journal of sports medicine
  • [ISO-abbreviation] Am J Sports Med
  • [Language] eng
  • [Grant] United States / PHS HHS / / R49/ CEOOO674-01
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


30. Lee EB, Kim JY, Zhao J, Park MH, Song YW: Haplotype association of IL-8 gene with Behcet's disease. Tissue Antigens; 2007 Feb;69(2):128-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haplotype association of IL-8 gene with Behcet's disease.
  • Interleukin-8 (IL-8), a CXC chemokine that recruits and activates inflammatory cells, plays a critical role in the pathogenesis of Behcet's disease (BD).
  • However, the frequency of haplotype TAT inferred from SNPs, IL-8 -353 A/T, -251 A/T and +678 T/C, was significantly higher in patients with BD than controls (5.9 vs 0.0%, P = 0.0001), as was haplotype ATC (6.7 vs 0.0%, P < 0.0001).

  • Genetic Alliance. consumer health - Behcet's Disease.
  • MedlinePlus Health Information. consumer health - Behcet's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17257314.001).
  • [ISSN] 0001-2815
  • [Journal-full-title] Tissue antigens
  • [ISO-abbreviation] Tissue Antigens
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / HLA-B Antigens; 0 / HLA-B51 Antigen; 0 / Interleukin-8; 0 / Receptors, Interleukin-8A; 0 / Receptors, Interleukin-8B
  •  go-up   go-down


31. Stedmon AW, Sharples S, Littlewood R, Cox G, Patel H, Wilson JR: Datalink in air traffic management: Human factors issues in communications. Appl Ergon; 2007 Jul;38(4):473-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using a novel air traffic control (ATC) task, two experiments are reported.

  • MedlinePlus Health Information. consumer health - Ergonomics.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17506976.001).
  • [ISSN] 0003-6870
  • [Journal-full-title] Applied ergonomics
  • [ISO-abbreviation] Appl Ergon
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


32. Zito G, Richiusa P, Bommarito A, Carissimi E, Russo L, Coppola A, Zerilli M, Rodolico V, Criscimanna A, Amato M, Pizzolanti G, Galluzzo A, Giordano C: In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines. PLoS One; 2008;3(10):e3544
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines.
  • BACKGROUND: Recent publications suggest that neoplastic initiation and growth are dependent on a small subset of cells, termed cancer stem cells (CSCs).
  • Anaplastic Thyroid Carcinoma (ATC) is a very aggressive solid tumor with poor prognosis, characterized by high dedifferentiation.
  • The existence of CSCs might account for the heterogeneity of ATC lesions.
  • METHODOLOGY/PRINCIPAL FINDINGS: ATC cell lines ARO, KAT-4, KAT-18 and FRO were analyzed for CD133 expression.
  • Furthermore, ARO/CD133(pos) showed levels of thyroid transcription factor TTF-1 similar to the fetal thyroid cell line TAD-2, while the expression in ARO/CD133(neg) was negligible.
  • CONCLUSIONS/SIGNIFICANCE: We describe CD133(pos) cells in ATC cell lines.
  • The simultaneous positivity for thyroid specific factor TTF-1 and onfFN suggest they might represent putative thyroid cancer stem-like cells.
  • Our in vitro findings might provide new insights for novel therapeutic approaches.
  • [MeSH-major] Antigens, CD / metabolism. Carcinoma / pathology. Glycoproteins / metabolism. Neoplastic Stem Cells / pathology. Peptides / metabolism. Thyroid Neoplasms / pathology


33. Jiang JY, Tseng FY: Prognostic factors of anaplastic thyroid carcinoma. J Endocrinol Invest; 2006 Jan;29(1):11-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors of anaplastic thyroid carcinoma.
  • BACKGROUND AND PURPOSE: Anaplastic thyroid carcinoma (ATC) is one of the most aggressive malignancies.
  • METHODS: A retrospective review was conducted of ATC patients in National Taiwan University Hospital from 1978 to 2003.
  • CONCLUSIONS: ATC is an aggressive malignancy.
  • [MeSH-major] Carcinoma / diagnosis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Goiter / complications. Humans. Leukocytosis / complications. Leukocytosis / diagnosis. Male. Middle Aged. Prognosis. Regression Analysis. Retrospective Studies. Serum Albumin / analysis. Survival Rate. Thyroxine / blood

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Endocrinol (Oxf). 1986 Mar;24(3):335-41 [2423275.001]
  • [Cites] Cancer. 1997 Feb 1;79(3):564-73 [9028369.001]
  • [Cites] Mayo Clin Proc. 1985 Jan;60(1):51-8 [3965822.001]
  • [Cites] Cancer. 1990 Jul 15;66(2):321-30 [1695118.001]
  • [Cites] Eur J Surg Oncol. 1992 Apr;18(2):83-8 [1582515.001]
  • [Cites] Surgery. 1991 Dec;110(6):956-61; discussion 961-3 [1745983.001]
  • [Cites] World J Surg. 1998 Jul;22(7):725-30 [9606289.001]
  • [Cites] Eur J Surg Oncol. 1993 Dec;19(6):511-6 [8270035.001]
  • [Cites] Ann Oncol. 2000 Sep;11(9):1083-9 [11061600.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1984;404(2):117-26 [6207659.001]
  • [Cites] Taiwan Yi Xue Hui Za Zhi. 1989 Jun;88(6):551-6 [2794956.001]
  • [Cites] Endocrinol Metab Clin North Am. 1996 Mar;25(1):49-68 [8907680.001]
  • [Cites] Curr Opin Oncol. 2003 Jan;15(1):78-83 [12490766.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2638-48 [9874472.001]
  • [Cites] Semin Diagn Pathol. 1985 May;2(2):123-36 [3843690.001]
  • [Cites] Langenbecks Arch Surg. 1999 Jun;384(3):284-93 [10437618.001]
  • [Cites] Otolaryngol Clin North Am. 2003 Feb;36(1):107-15 [12803012.001]
  • [Cites] J Immunol. 1986 Jun 1;136(11):4220-5 [3009619.001]
  • [Cites] World J Surg. 2001 May;25(5):617-22 [11369989.001]
  • [Cites] Cancer. 1998 Mar 15;82(6):1146-53 [9506362.001]
  • [Cites] Am J Med. 1983 Oct;75(4):702-4 [6624779.001]
  • [Cites] J Surg Oncol. 1996 Dec;63(4):251-5 [8982370.001]
  • [Cites] Cancer. 1994 Aug 15;74(4):1348-54 [8055459.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2335-42 [11413523.001]
  • [Cites] J Exp Med. 1986 Jun 1;163(6):1433-50 [3486936.001]
  • [Cites] Surgery. 2001 Dec;130(6):1028-34 [11742333.001]
  • [Cites] Semin Surg Oncol. 1999 Jan-Feb;16(1):64-9 [9890741.001]
  • [Cites] Endocrinol Metab Clin North Am. 1990 Sep;19(3):637-48 [2261909.001]
  • [Cites] Thyroid. 1998 Aug;8(8):715-26 [9737368.001]
  • [Cites] Endocrinol Jpn. 1989 Dec;36(6):905-7 [2633916.001]
  • [Cites] Am J Clin Pathol. 1985 Feb;83(2):135-58 [2578727.001]
  • [Cites] Thyroid. 1999 Oct;9(10):1029-32 [10560959.001]
  • [Cites] J Clin Invest. 1986 Jun;77(6):1857-63 [3486886.001]
  • [Cites] World J Surg. 1990 May-Jun;14(3):291-4; discussion 295 [2368431.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Apr;56(4):553-5 [11966749.001]
  • [Cites] Head Neck. 1996 Jan-Feb;18(1):36-41 [8774920.001]
  • [Cites] Hum Pathol. 1992 Nov;23(11):1252-61 [1330875.001]
  • [Cites] Am J Surg. 1999 Apr;177(4):337-9 [10326855.001]
  • [Cites] Head Neck. 1995 Jan-Feb;17(1):41-7; discussion 47-8 [7883548.001]
  • (PMID = 16553028.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Serum Albumin; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


34. Niepomniszcze H, Suárez H, Pitoia F, Pignatta A, Danilowicz K, Manavela M, Elsner B, Bruno OD: Follicular carcinoma presenting as autonomous functioning thyroid nodule and containing an activating mutation of the TSH receptor (T620I) and a mutation of the Ki-RAS (G12C) genes. Thyroid; 2006 May;16(5):497-503
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular carcinoma presenting as autonomous functioning thyroid nodule and containing an activating mutation of the TSH receptor (T620I) and a mutation of the Ki-RAS (G12C) genes.
  • Most autonomous functioning thyroid nodules (AFTN) are benign thyroid follicular neoplasms.
  • We report a case of follicular carcinoma presenting as an AFTN causing subclinical hyperthyroidism in a 64-year-old woman who had a 6-cm hot nodule in the left thyroid lobe.
  • Genomic DNA was extracted from paraffin-embedded tissues from the tumor and extratumoral thyroid tissue.
  • Sequence analyses revealed point mutations in two different genes: the normal ACC sequence at codon 620 of the TSHR gene was replaced by ATC, changing the threonine by isoleucine (T620I); and the wild-type GGT at codon 12 of Ki-RAS mutated to TGT, replacing glycine by cysteine (G12C).
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / genetics. Gene Expression Regulation, Neoplastic. Genes, ras / genetics. Mutation. Receptors, Thyrotropin / genetics. Thyroid Gland / pathology. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16756473.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon; 0 / Receptors, Thyrotropin; 9007-49-2 / DNA; E0399OZS9N / Cyclic AMP
  •  go-up   go-down


35. Nemenqani D, Yaqoob N, Khoja H: Leiomyosarcoma metastatic to the thyroid diagnosed by fine needle aspiration cytology. J Pak Med Assoc; 2010 Apr;60(4):307-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leiomyosarcoma metastatic to the thyroid diagnosed by fine needle aspiration cytology.
  • The thyroid gland is a known but an unusual site for metastatic tumours from various primary sites.
  • Primary smooth muscle tumours of thyroid are rare.
  • Leiomyosarcoma of the thyroid gland whether of primary or metastatic origin should be distinguished from anaplastic carcinoma.
  • Few cases of leiomyosarcoma metastatic to thyroid, diagnosed by fine needle aspiration cytology (FNAC) have been documented.
  • [MeSH-major] Biopsy, Fine-Needle. Leiomyosarcoma / secondary. Pelvic Neoplasms / pathology. Thyroid Neoplasms / secondary

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20419977.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


36. Laatikainen LE, Castellone MD, Hebrant A, Hoste C, Cantisani MC, Laurila JP, Salvatore G, Salerno P, Basolo F, Näsman J, Dumont JE, Santoro M, Laukkanen MO: Extracellular superoxide dismutase is a thyroid differentiation marker down-regulated in cancer. Endocr Relat Cancer; 2010 Sep;17(3):785-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extracellular superoxide dismutase is a thyroid differentiation marker down-regulated in cancer.
  • Reactive oxygen species, specifically hydrogen peroxide (H(2)O(2)), have a significant role in hormone production in thyroid tissue.
  • Although recent studies have demonstrated that dual oxidases are responsible for the H(2)O(2) synthesis needed in thyroid hormone production, our data suggest a pivotal role for superoxide dismutase 3 (SOD3) as a major H(2)O(2)-producing enzyme.
  • According to our results, Sod3 is highly expressed in normal thyroid, and becomes even more abundant in rat goiter models.
  • We showed TSH-stimulated expression of Sod3 via phospholipase C-Ca(2+) and cAMP-protein kinase A, a pathway that might be disrupted in thyroid cancer.
  • In line with this finding, we demonstrated an oncogene-dependent decrease in Sod3 mRNA expression synthesis in thyroid cancer cell models that corresponded to a similar decrease in clinical patient samples, suggesting that SOD3 could be used as a differentiation marker in thyroid cancer.
  • Finally, the functional analysis in thyroid models indicated a moderate role for SOD3 in regulating normal thyroid cell proliferation being in line with our previous observations.
  • [MeSH-major] Antigens, Differentiation / metabolism. Cell Differentiation. Superoxide Dismutase / metabolism. Thyroid Neoplasms / enzymology
  • [MeSH-minor] Animals. Blotting, Western. Calcium / metabolism. Carcinoma. Cell Proliferation. Down-Regulation. Humans. Hydrogen Peroxide / metabolism. Male. RNA, Messenger / genetics. RNA, Small Interfering / pharmacology. Rats. Rats, Sprague-Dawley. Reverse Transcriptase Polymerase Chain Reaction. Superoxides / metabolism. Thyroid Carcinoma, Anaplastic. Thyroid Gland / enzymology. Thyroid Gland / pathology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20576801.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Differentiation; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 11062-77-4 / Superoxides; BBX060AN9V / Hydrogen Peroxide; EC 1.15.1.1 / SOD3 protein, human; EC 1.15.1.1 / Sod3 protein, rat; EC 1.15.1.1 / Superoxide Dismutase; SY7Q814VUP / Calcium; Thyroid cancer, papillary
  •  go-up   go-down


37. Podtcheko A, Ohtsuru A, Namba H, Saenko V, Starenki D, Palona I, Sedliarou I, Rogounovitch T, Yamashita S: Inhibition of ABL tyrosine kinase potentiates radiation-induced terminal growth arrest in anaplastic thyroid cancer cells. Radiat Res; 2006 Jan;165(1):35-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of ABL tyrosine kinase potentiates radiation-induced terminal growth arrest in anaplastic thyroid cancer cells.
  • Gleevec, a selective tyrosine kinase inhibitor, retarded the growth of anaplastic thyroid cancer cell lines in vitro and in vivo through selective inhibition of ABL tyrosine kinase activity.
  • In the present study, we investigated the ability of Gleevec to modulate the in vitro and in vivo radiation response of anaplastic thyroid cancer cells.
  • Cell growth assays, colony formation assays and xenograft models were used to quantify the radiosensitizing effect of Gleevec in cells of the anaplastic thyroid cancer cell lines ARO and FRO.
  • Gleevec combined with radiation produced an increase in tumor growth inhibition compared to treatment with either modality alone in mice bearing anaplastic thyroid cancer xenografts.
  • The drug suppressed radiation-induced ABL activation and promoted CDKN1A (p21(cip1)) accumulation in irradiated anaplastic thyroid cancer cells.
  • [MeSH-major] Carcinoma / enzymology. Carcinoma / pathology. Piperazines / administration & dosage. Protein-Tyrosine Kinases / antagonists & inhibitors. Protein-Tyrosine Kinases / metabolism. Pyrimidines / administration & dosage. Thyroid Neoplasms / enzymology. Thyroid Neoplasms / pathology


38. Soto-Pérez-de-Celis E, González-Pezzat I: Anaplastic thyroid carcinoma. Intern Med J; 2010 May;40(5):383
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic thyroid carcinoma.
  • [MeSH-major] Carcinoma / radiography. Thyroid Neoplasms / radiography

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20575995.001).
  • [ISSN] 1445-5994
  • [Journal-full-title] Internal medicine journal
  • [ISO-abbreviation] Intern Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


39. Zitzelsberger H, Thomas G, Unger K: Chromosomal aberrations in thyroid follicular-cell neoplasia: in the search of novel oncogenes and tumour suppressor genes. Mol Cell Endocrinol; 2010 May 28;321(1):57-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal aberrations in thyroid follicular-cell neoplasia: in the search of novel oncogenes and tumour suppressor genes.
  • Thyroid cancer derived from the follicular cell is characterised by specific gene alterations that are closely linked to the various pathological types comprising papillary, follicular and anaplastic thyroid cancer.
  • This situation, coupled with the demonstration of genetic heterogeneity in thyroid cancer, is a strong motivation for the search of novel gene alterations.
  • Chromosomal aberrations are a good starting point to initiate this search and therefore the current knowledge on chromosomal alterations in thyroid follicular-cell neoplasia is reviewed in this article.
  • The identification of novel genetic markers in thyroid cancer will be further improved by integrative approaches combining data from genomic and expression analyses with clinical data.
  • This approach is powerful to identify genetic markers as well as new therapeutic targets in follicular-cell thyroid cancer.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Chromosome Aberrations. Genes, Tumor Suppressor. Oncogenes / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19961897.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Number-of-references] 110
  •  go-up   go-down


40. Närhi U, Vanakoski J, Sihvo S: Switching of H(2)-Receptor Antagonists to Over-the-Counter Status in Finland : Implications for Consumption and Adverse Effects. Clin Drug Investig; 2005;25(4):243-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied the consumption of H(2)-receptor antagonists, proton pump inhibitors, sucralfate and antacids (A02BA, A02BC, A02BX02 and A02A, respectively, according to the Anatomical Therapeutic Chemical [ATC] classification).
  • RESULTS: The total consumption of medicines for the treatment of peptic ulcer disease and gastro-oesophageal reflux disease increased more than 2-fold from 1990 to 2003 (from 12.8 daily defined doses [DDD]/1000 inhabitants/day to 29.6 DDD/1000 inhabitants/day).
  • Since 1998, proton pump inhibitors have been the most commonly used drug group for the treatment of peptic ulcer and gastro-oesophageal reflux disease in Finland.
  • In 2003, the consumption of proton pump inhibitors was 75% (22.2 DDD/1000 inhabitants/day) of the total consumption of drugs for the treatment of peptic ulcer and gastro-oesophageal reflux disease.
  • However, the total number of reports concerning these ATC groups in the national ADR database is not very high, and therefore patient-based surveys are needed to verify this finding.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacol Toxicol. 1991 Oct;69(4):253-8 [1683484.001]
  • [Cites] Scand J Gastroenterol. 1997 Sep;32(9):855-61 [9299660.001]
  • (PMID = 17523774.001).
  • [ISSN] 1173-2563
  • [Journal-full-title] Clinical drug investigation
  • [ISO-abbreviation] Clin Drug Investig
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  •  go-up   go-down


41. Knopf H: [Medicine use in children and adolescents. Data collection and first results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2007 May-Jun;50(5-6):863-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most frequently, the boys and girls used medicines for the treatment of respiratory tract conditions (ATC code R00: 16.8%).
  • This was followed by Alimentary System and Metabolism (ATC code A00: 16.0%) and Dermatological Preparations (ATC code D00: 9.7%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17514472.001).
  • [ISSN] 1436-9990
  • [Journal-full-title] Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
  • [ISO-abbreviation] Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


42. Noh TW, Soung YH, Kim HI, Gil HJ, Kim JM, Lee EJ, Chung J: Effect of {beta}4 integrin knockdown by RNA interference in anaplastic thyroid carcinoma. Anticancer Res; 2010 Nov;30(11):4485-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of {beta}4 integrin knockdown by RNA interference in anaplastic thyroid carcinoma.
  • BACKGROUND: Integrin α6β4 is a known tumor antigen; however, its function in different subtypes of thyroid cancer is not known.
  • This study reports that α6β4 expression is selectively up-regulated in anaplastic thyroid cancer (ATC) cells, the most malignant subtype of human thyroid cancer.
  • MATERIALS AND METHODS: To assess the contribution of α6β4 in ATC progression, cell proliferation, motility and soft agar assay were performed in vitro and a xenograft tumor growth assay was performed in vivo.
  • RESULTS: Knockdown of β4 integrin subunit expression by shRNA in ATC cells reduced the proliferation, migration, and anchorage-independent growth of ATC cells in vitro and xenograft tumor growth in vivo.
  • CONCLUSION: These data suggest that integrin α6β4 contributes to the development of aggressive forms of thyroid cancer with poor prognostic potential, such as ATC, and thus may be a novel therapeutic target for the treatment for this subtype of thyroid cancer.
  • [MeSH-major] Carcinoma / genetics. Cell Movement. Cell Proliferation. Integrin alpha6beta4 / genetics. RNA Interference. RNA, Small Interfering / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21115897.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Integrin alpha6beta4; 0 / RNA, Messenger; 0 / RNA, Small Interfering
  •  go-up   go-down


43. Federico A, Pallante P, Bianco M, Ferraro A, Esposito F, Monti M, Cozzolino M, Keller S, Fedele M, Leone V, Troncone G, Chiariotti L, Pucci P, Fusco A: Chromobox protein homologue 7 protein, with decreased expression in human carcinomas, positively regulates E-cadherin expression by interacting with the histone deacetylase 2 protein. Cancer Res; 2009 Sep 1;69(17):7079-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromobox protein homologue 7 protein, with decreased expression in human carcinomas, positively regulates E-cadherin expression by interacting with the histone deacetylase 2 protein.
  • Chromobox protein homologue 7 (CBX7) is a chromobox family protein encoding a novel polycomb protein, the expression of which shows a progressive reduction, well related with the malignant grade of the thyroid neoplasias.
  • Indeed, CBX7 protein levels decreased in an increasing percentage of cases going from benign adenomas to papillary, follicular, and anaplastic thyroid carcinomas.
  • Consistent with these data, we found a positive statistical correlation between CBX7 and E-cadherin expression in human thyroid carcinomas.
  • [MeSH-major] Cadherins / metabolism. Carcinoma, Papillary / metabolism. Gene Expression Regulation, Neoplastic. Histone Deacetylases / metabolism. Repressor Proteins / biosynthesis. Repressor Proteins / metabolism

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19706751.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CBX7 protein, human; 0 / Cadherins; 0 / Histone Deacetylase Inhibitors; 0 / Histones; 0 / Repressor Proteins; EC 3.5.1.98 / Hdac2 protein, rat; EC 3.5.1.98 / Histone Deacetylase 2; EC 3.5.1.98 / Histone Deacetylases; EC 6.3.2.19 / Polycomb Repressive Complex 1
  •  go-up   go-down


44. Schubert I, Köster I, Lehmkuhl G: The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000-2007. Dtsch Arztebl Int; 2010 Sep;107(36):615-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000-2007.
  • BACKGROUND: The goal of this study is to assess changes in the prevalence of attention-deficit/hyperactivity disorder (ADHD) and methylphenidate prescriptions over the period 2000 to 2007 on the basis of data from a German statutory health insurance carrier.
  • Per calender year, 50,000 to 63,000 children and adolescents were retrospectively observed with respect to the documentation of ADHD diagnosis (ICD-10 diagnosis F90) and the prescribing of methylphenidate (ATC: N06BA04).
  • [MeSH-major] Attention Deficit Disorder with Hyperactivity / drug therapy. Attention Deficit Disorder with Hyperactivity / epidemiology. Central Nervous System Stimulants / therapeutic use. Methylphenidate / therapeutic use

  • Genetic Alliance. consumer health - Attention Deficit Disorder.
  • MedlinePlus Health Information. consumer health - Attention Deficit Hyperactivity Disorder.
  • Hazardous Substances Data Bank. METHYLPHENIDATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Psychiatr Serv. 2008 May;59(5):554-60 [18451016.001]
  • [Cites] Psychiatr Serv. 2009 Feb;60(2):269 [19176429.001]
  • [Cites] Prax Kinderpsychol Kinderpsychiatr. 2009;58(3):170-85 [19435152.001]
  • [Cites] Gesundheitswesen. 2004 Jun;66(6):387-92 [15206042.001]
  • [Cites] Eur J Clin Pharmacol. 2004 Jul;60(5):377-9 [15168100.001]
  • [Cites] Z Kinder Jugendpsychiatr Psychother. 2004 Jul;32(3):157-66 [15357012.001]
  • [Cites] J Child Adolesc Psychopharmacol. 2005 Feb;15(1):62-7 [15741787.001]
  • [Cites] Gesundheitswesen. 2005 Aug-Sep;67(8-9):638-45 [16217718.001]
  • [Cites] Am J Psychiatry. 2006 Apr;163(4):579-85 [16585430.001]
  • [Cites] Clin Drug Investig. 2006;26(3):161-7 [17163247.001]
  • [Cites] Aust N Z J Public Health. 2007 Apr;31(2):120-6 [17461001.001]
  • [Cites] Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2007 May-Jun;50(5-6):827-35 [17514469.001]
  • [Cites] Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2007 May-Jun;50(5-6):871-8 [17514473.001]
  • [Cites] Gesundheitswesen. 2007 May;69(5):292-6 [17582546.001]
  • [Cites] Tidsskr Nor Laegeforen. 2007 Sep 20;127(18):2360-2 [17895938.001]
  • [Cites] Rev Epidemiol Sante Publique. 2007 Oct;55(5):357-63 [17889474.001]
  • [Cites] Laeknabladid. 2007 Dec;93(12):825-32 [18057472.001]
  • [Cites] Eur Child Adolesc Psychiatry. 2007 Oct;16(7):430-8 [17468967.001]
  • [Cites] Eur J Clin Pharmacol. 2008 Mar;64(3):311-7 [18026941.001]
  • [Cites] Psychiatr Serv. 2008 May;59(5):507-14 [18451006.001]
  • [CommentIn] Dtsch Arztebl Int. 2010 Dec;107(51-52):919; author reply 919-20 [21249142.001]
  • (PMID = 20948775.001).
  • [ISSN] 1866-0452
  • [Journal-full-title] Deutsches Ärzteblatt international
  • [ISO-abbreviation] Dtsch Arztebl Int
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Central Nervous System Stimulants; 207ZZ9QZ49 / Methylphenidate
  • [Other-IDs] NLM/ PMC2947846
  •  go-up   go-down


45. van de Vrie-Hoekstra NW, de Vries TW, van den Berg PB, Brouwer OF, de Jong-van den Berg LT: Antiepileptic drug utilization in children from 1997-2005--a study from the Netherlands. Eur J Clin Pharmacol; 2008 Oct;64(10):1013-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: From the Dutch Interaction Database (IADB.nl) we selected children aged 0-19 years who received at least one prescription for an AED (ATC-code beginning with N03A) between 1997 and 2005.
  • The 50% survival probability (= time period when 50% of children had stopped using AEDs) was around 2 years, with a significantly lower discontinuation of treatment for girls than boys (P = 0.04).
  • [MeSH-major] Anticonvulsants / therapeutic use. Epilepsy / drug therapy
  • [MeSH-minor] Carbamazepine / administration & dosage. Carbamazepine / adverse effects. Carbamazepine / therapeutic use. Child. Databases, Factual. Drug Utilization. Female. Humans. Incidence. Male. Netherlands / epidemiology. Practice Guidelines as Topic. Prevalence. Retrospective Studies. Triazines / administration & dosage. Triazines / adverse effects. Triazines / therapeutic use. Valproic Acid / administration & dosage. Valproic Acid / adverse effects. Valproic Acid / therapeutic use

  • MedlinePlus Health Information. consumer health - Epilepsy.
  • Hazardous Substances Data Bank. CARBAMAZEPINE .
  • Hazardous Substances Data Bank. LAMOTRIGINE .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain. 2004 Aug;127(Pt 8):1774-84 [15201192.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2004 Mar;13(3):173-9 [15072117.001]
  • [Cites] Br J Clin Pharmacol. 2006 Dec;62(6):660-5 [16796700.001]
  • [Cites] Acta Neurol Scand. 2006 Jun;113(6):405-11 [16674607.001]
  • [Cites] BMJ. 1997 Jan 18;314(7075):180-1 [9022432.001]
  • [Cites] Br J Clin Pharmacol. 2007 Jun;63(6):689-97 [17257162.001]
  • [Cites] Neurology. 2004 Apr 27;62(8):1252-60 [15111659.001]
  • [Cites] Psychiatr Serv. 2006 May;57(5):681-5 [16675763.001]
  • [Cites] N Engl J Med. 1999 Aug 12;341(7):485-9 [10441604.001]
  • [Cites] Acta Neurol Scand. 2001 Jul;104(1):6-11 [11442436.001]
  • [Cites] Eur J Paediatr Neurol. 2006 May;10(3):107-13 [16638642.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2005 Apr;14(4):239-47 [15719354.001]
  • [Cites] Neurology. 2006 Mar 28;66(6 Suppl 3):S37-45 [16567741.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1995 Jan;58(1):44-50 [7823066.001]
  • [Cites] Epilepsia. 2002 Nov;43(11):1402-9 [12423392.001]
  • (PMID = 18618103.001).
  • [ISSN] 1432-1041
  • [Journal-full-title] European journal of clinical pharmacology
  • [ISO-abbreviation] Eur. J. Clin. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Triazines; 33CM23913M / Carbamazepine; 614OI1Z5WI / Valproic Acid; U3H27498KS / lamotrigine
  •  go-up   go-down


46. Lewandowski W, Matsakis D, Panfilo G, Tavella P: Analysis of correlations, and link and equipment noise in the uncertainties of [UTC - UTC(k)]. IEEE Trans Ultrason Ferroelectr Freq Control; 2008 Apr;55(4):750-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of correlations, and link and equipment noise in the uncertainties of [UTC - UTC(k)].
  • We refine our estimate of the uncertainty in [UTC - UTC(k)] by taking into account the contribution of correlations between the links.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18467219.001).
  • [ISSN] 0885-3010
  • [Journal-full-title] IEEE transactions on ultrasonics, ferroelectrics, and frequency control
  • [ISO-abbreviation] IEEE Trans Ultrason Ferroelectr Freq Control
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Wagstaff AS, Arva P: Hearing loss in civilian airline and helicopter pilots compared to air traffic control personnel. Aviat Space Environ Med; 2009 Oct;80(10):857-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: In order to investigate possible hearing loss as a consequence of aviation noise, a comparative analysis of audiometric data from Norwegian Air Traffic Control (ATC) personnel, airline (fixed-wing) pilots, and helicopter pilots was performed.
  • METHODS: Male ATC, airline, and helicopter pilots were selected randomly from the Civil Aviation Authority (CAA) medical files.
  • There were 182 subjects included in the study: 50, 81, and 51 subjects for ATC, helicopter, and airline pilots, respectively.

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19817237.001).
  • [ISSN] 0095-6562
  • [Journal-full-title] Aviation, space, and environmental medicine
  • [ISO-abbreviation] Aviat Space Environ Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Fujita T, Ogasawara Y, Naito M, Doihara H, Shimizu N: Anaplastic thyroid carcinoma associated with granulocyte colony-stimulating factor: report of a case. Surg Today; 2006;36(1):63-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic thyroid carcinoma associated with granulocyte colony-stimulating factor: report of a case.
  • She had undergone a resection of thyroid carcinoma 13 years earlier, followed by two subsequent operations for recurrent thyroid disease.
  • Surgery was thus performed to control persistent bleeding from the axillary ulcer, and a histopathological examination resulted in a diagnosis of poorly differentiated thyroid carcinoma.
  • [MeSH-major] Carcinoma, Papillary / complications. Granulocyte Colony-Stimulating Factor. Leukocytosis / etiology. Thyroid Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nihon Kokyuki Gakkai Zasshi. 2000 May;38(5):391-7 [10921287.001]
  • [Cites] Intern Med. 1995 Jun;34(6):584-8 [7549149.001]
  • [Cites] J Otolaryngol. 2000 Jun;29(3):174-8 [10883833.001]
  • [Cites] Cancer Res. 1989 Sep 1;49(17):4740-6 [2474371.001]
  • [Cites] Am J Gastroenterol. 1999 Jan;94(1):273-5 [9934773.001]
  • [Cites] Am J Gastroenterol. 2001 Jan;96(1):258-9 [11197273.001]
  • [Cites] Cancer. 1990 May 1;65(9):1971-9 [2196988.001]
  • [Cites] Intern Med. 1992 Feb;31(2):277-80 [1376180.001]
  • [Cites] Surg Today. 1995;25(2):158-60 [7539648.001]
  • [Cites] Jpn J Clin Oncol. 1991 Dec;21(6):395-9 [1666658.001]
  • [Cites] Intern Med. 1996 Oct;35(10):815-20 [8933194.001]
  • [Cites] Cancer. 1989 Dec 1;64(11):2250-3 [2804915.001]
  • [Cites] Nihon Naika Gakkai Zasshi. 1979 Nov;68(11):1466-72 [533818.001]
  • [Cites] Thyroid. 2000 Dec;10(12):1113-8 [11201858.001]
  • [Cites] J Clin Ultrasound. 1990 Jun;18(5):438-41 [2161019.001]
  • [Cites] Blood. 1977 May;49(5):845-52 [300638.001]
  • [Cites] J Gastroenterol. 2003;38(10):1013-5 [14614613.001]
  • (PMID = 16378196.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


49. Lacroix L, Soria JC, Bidart JM, Schlumberger M: [Oncogenes and thyroid tumors]. Bull Cancer; 2005 Jan;92(1):37-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Oncogenes and thyroid tumors].
  • [Transliterated title] Oncogènes et tumeurs de la thyroïde.
  • Papillary thyroid carcinomas are characterized in 70% of cases by the presence of either a RET/PTC rearrangement, or an activating point mutation of RAS or BRAF genes that induce a constitutive activation of the MAP kinase pathway.
  • Follicular carcinomas are characterized by the presence of a RAS mutation or of a PAX8-PPARgamma rearrangement.
  • Inactivating mutations of the p53 gene are found only in anaplastic thyroid carcinomas.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Carcinoma, Papillary / genetics. Gene Rearrangement / genetics. Oncogenes / genetics. Point Mutation / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15689324.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Oncogene Proteins; 0 / Oncogene Proteins, Fusion; 0 / PAX8 protein, human; 0 / PPAR gamma; 0 / Paired Box Transcription Factors; 0 / Proto-Oncogene Proteins; 0 / Receptors, Growth Factor; 0 / Trans-Activators; 0 / oncogene protein trk; EC 2.7.10.1 / MET protein, human; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-met; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / ret-PTC fusion oncoproteins, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  • [Number-of-references] 39
  •  go-up   go-down


50. Al-Watban FA, Zhang XY: Photodynamic therapy of human undifferentiated thyroid carcinoma-bearing nude mice using topical 5-aminolevulinic acid. Photomed Laser Surg; 2005 Apr;23(2):206-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of human undifferentiated thyroid carcinoma-bearing nude mice using topical 5-aminolevulinic acid.
  • OBJECTIVE: We determined and evaluated the effect of photodynamic therapy (PDT) using topical 5-aminolevulinic acid (ALA) cream in treating human undifferentiated thyroid carcinoma (UTC)-bearing nude mice.
  • BACKGROUND DATA: UTC constitutes almost 10% of thyroid cancers and shows a very poor response to chemotherapy.
  • MATERIALS AND METHODS: UTC tumor was implanted in the right flank of the nude mice after anesthesia.
  • CONCLUSIONS: PDT is effective in delaying the growth of UTC-bearing nude mice using topical ALA cream and laser light with inappropriate parameters.
  • [MeSH-major] Aminolevulinic Acid / pharmacology. Carcinoma / therapy. Photochemotherapy. Photosensitizing Agents / pharmacology. Thyroid Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15910188.001).
  • [ISSN] 1549-5418
  • [Journal-full-title] Photomedicine and laser surgery
  • [ISO-abbreviation] Photomed Laser Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


51. Aguilar G, Jover JL, Soro M, Belda FJ, García-Raimundo M, Maruenda A: Additional work of breathing and breathing patterns in spontaneously breathing patients during pressure support ventilation, automatic tube compensation and amplified spontaneous pattern breathing. Eur J Anaesthesiol; 2005 Apr;22(4):312-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Additional work of breathing and breathing patterns in spontaneously breathing patients during pressure support ventilation, automatic tube compensation and amplified spontaneous pattern breathing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15892412.001).
  • [ISSN] 0265-0215
  • [Journal-full-title] European journal of anaesthesiology
  • [ISO-abbreviation] Eur J Anaesthesiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Letter
  • [Publication-country] England
  •  go-up   go-down


52. Takarabe M, Okuda S, Itoh M, Tokimatsu T, Goto S, Kanehisa M: Network analysis of adverse drug interactions. Genome Inform; 2008;20:252-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We defined drug target and drug-metabolizing enzymes as interaction factors using information on them in KEGG DRUG, and classified drugs into pharmacological/chemical subgroups.
  • To characterize other interactions without interaction factors, we used the ATC classification system and found an association between interaction mechanisms and pharmacological/chemical subgroups.

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19425139.001).
  • [ISSN] 0919-9454
  • [Journal-full-title] Genome informatics. International Conference on Genome Informatics
  • [ISO-abbreviation] Genome Inform
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Pharmaceutical Preparations; 0 / Receptors, Biogenic Amine; EC 1.14.14.1 / Cytochrome P-450 CYP3A
  •  go-up   go-down


53. Hassan I, Wunderlich A, Slater E, Hoffmann S, Celik I, Zielke A: Antisense p53 decreases production of VEGF in follicular thyroid cancer cells. Endocrine; 2006 Jun;29(3):409-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antisense p53 decreases production of VEGF in follicular thyroid cancer cells.
  • Inactivating mutations of wild-type p53 (WTp53) tumor suppressor gene are common in anaplastic thyroid cancer (ATC) and are associated with poor prognosis.
  • Therefore, the potential of MTp53 knockout by oligodeoxyribonucleotide phosphorothioates (ODNs) to affect VEGF production of undifferentiated thyroid cancer cells with a recessive MTp53 mutation was evaluated.
  • Transfection of undifferentiated thyroid cancer cells with ODN reduced VEGF secretion of FTC-133 cells following transfection by 34% as compared to the negative control (cells transfected with ODN-HIV; p = 0.03).
  • These results suggest that transient MTp53 knockout with ODNs complementary to p53 nucleotide sequences impair secretion of VEGF in the undifferentiated thyroid cancer cell line FTC-133.
  • [MeSH-major] Adenocarcinoma, Follicular / metabolism. Gene Silencing / physiology. Thyroid Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism. Vascular Endothelial Growth Factor A / biosynthesis

  • Genetic Alliance. consumer health - Thyroid cancer, follicular.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 1997 Sep;66(1):11-8 [9290687.001]
  • [Cites] Anticancer Res. 2000 Jul-Aug;20(4):2723-8 [10953350.001]
  • [Cites] Thyroid. 2002 Nov;12(11):953-61 [12490072.001]
  • [Cites] Science. 1994 Sep 9;265(5178):1582-4 [7521539.001]
  • [Cites] Cancer Res. 1986 Feb;46(2):467-73 [2416426.001]
  • [Cites] Langenbecks Arch Surg. 1998 Aug;383(3-4):269-75 [9776455.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Oct;83(10):3668-72 [9768682.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Nov;82(11):3741-7 [9360534.001]
  • [Cites] Leuk Lymphoma. 1994 Jan;12(3-4):223-31 [8167553.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):671-7 [10934169.001]
  • [Cites] Surgery. 2001 Dec;130(6):1028-34 [11742333.001]
  • [Cites] Science. 2002 Feb 22;295(5559):1526-8 [11859195.001]
  • [Cites] Science. 1993 Aug 20;261(5124):1004-12 [8351515.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Dec;89(12):6139-45 [15579770.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Oct;81(10):3498-504 [8855792.001]
  • [Cites] Cancer Res. 1995 Dec 15;55(24):6161-5 [8521408.001]
  • [Cites] Ann Clin Lab Sci. 2003 Spring;33(2):192-9 [12817624.001]
  • [Cites] Horm Res. 1997;47(4-6):145-57 [9167946.001]
  • (PMID = 16943578.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oligodeoxyribonucleotides, Antisense; 0 / Tumor Suppressor Protein p53; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


54. McCrory P, Meeuwisse W, Johnston K, Dvorak J, Aubry M, Molloy M, Cantu R: Consensus statement on concussion in sport - the Third International Conference on Concussion in Sport held in Zurich, November 2008. Phys Sportsmed; 2009 Jun;37(2):141-59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This document is developed for use by physicians, therapists, certified athletic trainers, health professionals, coaches and other people involved in the care of injured athletes, whether at the recreational, elite, or professional level.
  • [MeSH-major] Athletic Injuries. Brain Concussion

  • MedlinePlus Health Information. consumer health - Concussion.
  • MedlinePlus Health Information. consumer health - Sports Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20048521.001).
  • [ISSN] 0091-3847
  • [Journal-full-title] The Physician and sportsmedicine
  • [ISO-abbreviation] Phys Sportsmed
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 148
  •  go-up   go-down


55. Tedelind S, Poliakova K, Valeta A, Hunegnaw R, Yemanaberhan EL, Heldin NE, Kurebayashi J, Weber E, Kopitar-Jerala N, Turk B, Bogyo M, Brix K: Nuclear cysteine cathepsin variants in thyroid carcinoma cells. Biol Chem; 2010 Aug;391(8):923-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear cysteine cathepsin variants in thyroid carcinoma cells.
  • The cysteine peptidase cathepsin B is important in thyroid physiology by being involved in thyroid prohormone processing initiated in the follicular lumen and completed in endo-lysosomal compartments.
  • However, cathepsin B has also been localized to the extrafollicular space and is therefore suggested to promote invasiveness and metastasis in thyroid carcinomas through, e.g., ECM degradation.
  • In this study, immunofluorescence and biochemical data from subcellular fractionation revealed that cathepsin B, in its single- and two-chain forms, is localized to endo-lysosomes in the papillary thyroid carcinoma cell line KTC-1 and in the anaplastic thyroid carcinoma cell lines HTh7 and HTh74.
  • This distribution is not affected by thyroid stimulating hormone (TSH) incubation of HTh74, the only cell line that expresses a functional TSH-receptor.
  • As deduced from co-localization studies and in vitro degradation assays, we suggest that nuclear variants of cathepsins are involved in the development of thyroid malignancies through modification of DNA-associated proteins.
  • [MeSH-major] Carcinoma / enzymology. Cathepsin B / metabolism. Cell Nucleus / enzymology. Genetic Variation. Thyroid Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Immunol. 2000 Feb;12(1):107-13 [10679409.001]
  • [Cites] Biochim Biophys Acta. 2000 Mar 7;1477(1-2):98-111 [10708852.001]
  • [Cites] Bioessays. 2000 Sep;22(9):861-7 [10944589.001]
  • [Cites] Chem Biol. 2000 Aug;7(8):569-81 [11048948.001]
  • [Cites] Biol Chem. 2001 May;382(5):717-25 [11517924.001]
  • [Cites] Biol Chem. 2001 May;382(5):735-41 [11517926.001]
  • [Cites] Biol Chem. 2001 May;382(5):867-70 [11517943.001]
  • [Cites] Bioinformatics. 2001 Aug;17(8):721-8 [11524373.001]
  • [Cites] Cancer Cell. 2004 May;5(5):443-53 [15144952.001]
  • [Cites] J Biol Chem. 2004 Sep 24;279(39):41012-7 [15262981.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Cancer Metastasis Rev. 1984;3(3):249-63 [6093995.001]
  • [Cites] Biol Cell. 1985;54(2):123-33 [2933102.001]
  • [Cites] Thyroidology. 1991 Dec;3(3):127-31 [1726928.001]
  • [Cites] DNA Cell Biol. 1993 May;12(4):299-309 [8494608.001]
  • [Cites] J Biol Chem. 1994 Apr 29;269(17):13030-5 [8175723.001]
  • [Cites] EMBO J. 1994 Aug 1;13(15):3430-7 [8062819.001]
  • [Cites] Gene. 1995 Jul 4;159(2):143-9 [7622042.001]
  • [Cites] Auris Nasus Larynx. 1995;22(1):43-8 [7677635.001]
  • [Cites] Endocrinology. 1996 May;137(5):1963-74 [8612537.001]
  • [Cites] Int J Cancer. 1996 May 16;66(4):420-6 [8635854.001]
  • [Cites] J Cell Biol. 1997 Jun 2;137(5):965-74 [9166399.001]
  • [Cites] Int J Biochem Cell Biol. 1997 May;29(5):715-20 [9251238.001]
  • [Cites] EMBO J. 2001 Sep 3;20(17):4629-33 [11532926.001]
  • [Cites] Mol Biol Cell. 2001 Dec;12(12):3808-20 [11739782.001]
  • [Cites] J Biol Chem. 2002 Apr 12;277(15):13192-201 [11821386.001]
  • [Cites] Biol Chem. 2002 May;383(5):773-84 [12108542.001]
  • [Cites] Science. 1998 Apr 24;280(5363):547-53 [9554838.001]
  • [Cites] J Biol Chem. 1998 May 22;273(21):13236-44 [9582368.001]
  • [Cites] Eur J Cell Biol. 1998 May;76(1):53-62 [9650783.001]
  • [Cites] Biochemistry. 1999 Feb 23;38(8):2377-85 [10029531.001]
  • [Cites] Thyroid. 1999 Jun;9(6):569-77 [10411119.001]
  • [Cites] J Mol Biol. 2005 Apr 22;348(1):85-100 [15808855.001]
  • [Cites] FEBS J. 2005 May;272(9):2118-31 [15853797.001]
  • [Cites] BMC Cell Biol. 2005;6(1):16 [15807897.001]
  • [Cites] Cell. 2005 Sep 23;122(6):957-68 [16169070.001]
  • [Cites] Nat Chem Biol. 2005 Sep;1(4):186-7 [16408029.001]
  • [Cites] Genes Dev. 2006 Mar 1;20(5):543-56 [16481467.001]
  • [Cites] Mol Cell Biol. 2006 Jun;26(11):4172-84 [16705169.001]
  • [Cites] Biol Chem. 2006 Sep;387(9):1285-93 [16972798.001]
  • [Cites] Nat Rev Cancer. 2006 Oct;6(10):764-75 [16990854.001]
  • [Cites] Curr Pharm Des. 2007;13(4):387-403 [17311556.001]
  • [Cites] Mol Cancer Res. 2007 Sep;5(9):899-907 [17855659.001]
  • [Cites] Cell. 2007 Sep 21;130(6):1108-19 [17889653.001]
  • [Cites] Eur J Cell Biol. 2007 Dec;86(11-12):747-61 [17651862.001]
  • [Cites] J Biol Chem. 2007 Dec 21;282(51):36980-6 [17923478.001]
  • [Cites] Biochimie. 2008 Feb;90(2):194-207 [17825974.001]
  • [Cites] Biochimie. 2008 Feb;90(2):380-6 [17991442.001]
  • [Cites] Expert Rev Proteomics. 2008 Oct;5(5):721-30 [18937562.001]
  • [Cites] Cell. 2008 Oct 17;135(2):284-94 [18957203.001]
  • [Cites] Int J Cancer. 2009 Jul 1;125(1):54-61 [19291794.001]
  • [Cites] Biol Chem. 2009 May-Jun;390(5-6):471-80 [19284293.001]
  • [Cites] J Biol Chem. 2009 Aug 14;284(33):21783-7 [19473965.001]
  • [Cites] BMC Biochem. 2009;10:23 [19772638.001]
  • [Cites] J Biol Chem. 2010 Mar 26;285(13):10078-86 [20075068.001]
  • [Cites] J Cell Sci. 2002 Dec 15;115(Pt 24):4877-89 [12432075.001]
  • [Cites] J Clin Invest. 2003 Jun;111(11):1733-45 [12782676.001]
  • [Cites] Mol Cell. 2004 Apr 23;14(2):207-19 [15099520.001]
  • [Cites] Cancer Cell. 2004 May;5(5):409-10 [15144947.001]
  • (PMID = 20536394.001).
  • [ISSN] 1437-4315
  • [Journal-full-title] Biological chemistry
  • [ISO-abbreviation] Biol. Chem.
  • [Language] eng
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB005011; United States / NCRR NIH HHS / RR / U54 RR020843
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Isoenzymes; 0 / Nuclear Proteins; 0 / Protein Subunits; 0 / RNA, Messenger; 0 / Receptors, Thyrotropin; 9002-71-5 / Thyrotropin; EC 3.4.- / Cathepsins; EC 3.4.22.- / Cysteine Endopeptidases; EC 3.4.22.1 / CTSB protein, human; EC 3.4.22.1 / Cathepsin B; EC 3.4.22.43 / CTSL2 protein, human
  • [Other-IDs] NLM/ NIHMS424136; NLM/ PMC3518386
  •  go-up   go-down


56. Troch M, Koperek O, Scheuba C, Dieckmann K, Hoffmann M, Niederle B, Raderer M: High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel. J Clin Endocrinol Metab; 2010 Sep;95(9):E54-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel.
  • CONTEXT: Anaplastic thyroid carcinoma (ATC) is a rare but aggressive solid tumor with a very short survival time even with multimodality treatment.
  • In view of in vitro data and the high rate of p53 mutations in ATC, we have used combined treatment with external beam radiation and docetaxel.
  • PATIENTS: A total of six patients with ATC were treated at our institution.
  • CONCLUSION: The preliminary data suggest that the combination of radiation and concomitant docetaxel is highly effective in patients with ATC.
  • However, a formal phase II study is needed to assess the therapeutic potential of this combination.
  • [MeSH-major] Carcinoma / drug therapy. Carcinoma / radiotherapy. Taxoids / therapeutic use. Thyroid Neoplasms / drug therapy. Thyroid Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Cell Differentiation. Chemotherapy, Adjuvant. Combined Modality Therapy. Dose Fractionation. Female. Humans. Male. Middle Aged. Radiotherapy Dosage. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Thyroid cancer, anaplastic.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20591979.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Taxoids; 15H5577CQD / docetaxel
  •  go-up   go-down


57. Cheng SP, Yin PH, Chang YC, Lee CH, Huang SY, Chi CW: Differential roles of leptin in regulating cell migration in thyroid cancer cells. Oncol Rep; 2010 Jun;23(6):1721-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential roles of leptin in regulating cell migration in thyroid cancer cells.
  • Excess body weight is associated with a moderately increased risk of thyroid cancer.
  • Adipocyte-derived hormone, leptin, has been shown to enhance cell growth and migration in many cancer types.
  • Limited evidence suggests that leptin has direct actions on the thyroid gland, but there are no data available on the effect of leptin on thyroid cancer cells.
  • We evaluated the action of leptin on gene expression, cell growth, cell cycle, and cell migration in anaplastic (ARO), follicular (WRO) and papillary (CGTH-W3) thyroid carcinoma cell lines.
  • Expression of long-form leptin receptors was observed in all thyroid cancer cell lines.
  • However, leptin was able to promote cell migration of papillary thyroid cancer cells, but inhibited migration of anaplastic and follicular cancer cells.
  • In summary, our study suggests that leptin modulates cell migration of thyroid cancer cells in a cell type-specific manner.
  • [MeSH-major] Adenocarcinoma, Follicular / metabolism. Carcinoma / metabolism. Carcinoma, Papillary / metabolism. Cell Movement. Leptin / metabolism. Thyroid Neoplasms / metabolism

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20428831.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Leptin; 0 / RNA, Messenger; 0 / Receptors, Leptin
  •  go-up   go-down


58. Takano T: [Fetal cell carcinogenesis hypothesis and the prospect of future laboratory tests]. Rinsho Byori; 2009 Aug;57(8):761-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A novel hypothesis of carcinogenesis, the "fetal cell carcinogenesis" hypothesis, was established based on molecular evidence of thyroid carcinoma.
  • In this hypothesis, cancer cells are derived directly from the remnants of fetal cells, instead of well-differentiated somatic cells by de-differentiation.
  • For example, thyroid cancer cells are generated from three types of fetal thyroid cell, namely, thyroid stem cells (TSCs), thyroblasts, and prothyrocytes by proliferation without differentiation, which results in producing anaplastic, papillary, and follicular carcinoma, respectively.
  • Genomic alternations, such as RET/PTC and PAX8-PPARgamma1 rearrangements and a mutation in the BRAF gene, play an oncogenic role by preventing thyroid fetal cells from differentiating.
  • Fetal cell carcinogenesis effectively explains recent molecular evidence regarding cancer, including cancer stem cells, and it underscores the importance of identifying a stem cells and clarifying the molecular mechanism of organ development in cancer research.
  • [MeSH-major] Clinical Laboratory Techniques. Neoplastic Stem Cells / pathology. Thyroid Neoplasms / genetics. Thyroid Neoplasms / pathology
  • [MeSH-minor] Cell Transformation, Neoplastic. Gene Expression Profiling. Gene Rearrangement. Humans. Mutation. Paired Box Transcription Factors / genetics. Proto-Oncogene Proteins B-raf / genetics. Proto-Oncogene Proteins c-ret / genetics. Thyroid Gland / embryology. Thyroid Gland / pathology

  • MedlinePlus Health Information. consumer health - Laboratory Tests.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19764411.001).
  • [ISSN] 0047-1860
  • [Journal-full-title] Rinsho byori. The Japanese journal of clinical pathology
  • [ISO-abbreviation] Rinsho Byori
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / PAX8 protein, human; 0 / Paired Box Transcription Factors; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  • [Number-of-references] 9
  •  go-up   go-down


59. Sun F, Sun Y, Yu Z, Zhang D, Zhang J, Song B, Zheng H: Interleukin-10 gene polymorphisms influence susceptibility to cachexia in patients with low-third gastric cancer in a Chinese population. Mol Diagn Ther; 2010 Apr 01;14(2):95-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-10 gene polymorphisms influence susceptibility to cachexia in patients with low-third gastric cancer in a Chinese population.
  • Therefore, we designed this study to investigate whether polymorphisms of the IL10 gene were associated with cachexia in patients with low-third gastric cancer in a Chinese population.
  • METHODS: 190 patients with low-third gastric cancer were included in this study.
  • In a logistic regression analysis adjusted for actual weight and carcinoma stage, the -1082AG genotype was associated with an odds ratio (OR) of 2.45 (95% CI 1.21, 4.96; p = 0.01), and the -819CC genotype was associated with an OR of 3.70 (95% CI 1.20, 11.39; p = 0.02) for cachexia.
  • Furthermore, haplotype analysis of the -1082A/G, -819T/C, and -592A/C SNPs revealed that at least five haplotypes (ATA, ACC, GCC, ACA, and ATC) were present in this Chinese population, and the -1082G/-819C/-592C (GCC) haplotype was associated with a significantly increased risk of cachexia as compared with the ATA haplotype (OR = 2.42; 95% CI 1.17, 5.00; p = 0.02).
  • CONCLUSION: Our results indicate that genetic polymorphisms of IL-10 may influence susceptibility to cachexia in patients with low-third gastric cancer in this Chinese population.
  • [MeSH-major] Asian Continental Ancestry Group / genetics. Cachexia / complications. Cachexia / genetics. Genetic Predisposition to Disease. Interleukin-10 / genetics. Polymorphism, Single Nucleotide / genetics. Stomach Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 1999 Aug;30(2):526-30 [10421663.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2006 Sep;9(5):603-6 [16912557.001]
  • [Cites] J Infect Dis. 2009 Feb 1;199(3):451-4 [19099482.001]
  • [Cites] Immunogenetics. 2003 Mar;54(12):896-9 [12671741.001]
  • [Cites] J Dermatol Sci. 2005 Feb;37(2):111-3 [15659329.001]
  • [Cites] Eur J Immunogenet. 1997 Feb;24(1):1-8 [9043871.001]
  • [Cites] Am J Clin Nutr. 2009 Apr;89(4):1164-72 [19244371.001]
  • [Cites] Support Care Cancer. 2008 Mar;16(3):229-34 [18071761.001]
  • [Cites] Eur J Immunogenet. 2002 Jun;29(3):237-40 [12047360.001]
  • [Cites] Nutrition. 2005 Sep;21(9):977-85 [16043325.001]
  • [Cites] Int J Cancer. 2003 May 1;104(5):617-23 [12594817.001]
  • [Cites] J Leukoc Biol. 2005 Nov;78(5):1043-51 [16204623.001]
  • [Cites] Ann N Y Acad Sci. 1996 Oct 31;795:410-2 [8958969.001]
  • [Cites] CA Cancer J Clin. 2002 Mar-Apr;52(2):72-91 [11929007.001]
  • [Cites] Am J Clin Nutr. 2006 Jun;83(6):1345-50 [16762946.001]
  • [Cites] Oncologist. 2007;12 Suppl 1:22-34 [17573453.001]
  • [Cites] Transpl Immunol. 1998 Sep;6(3):193-7 [9848226.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2009 May;12(3):227-31 [19339883.001]
  • (PMID = 20359252.001).
  • [ISSN] 1179-2000
  • [Journal-full-title] Molecular diagnosis & therapy
  • [ISO-abbreviation] Mol Diagn Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 130068-27-8 / Interleukin-10
  •  go-up   go-down


60. Gartner W, Mineva I, Daneva T, Baumgartner-Parzer S, Niederle B, Vierhapper H, Weissel M, Wagner L: A newly identified RET proto-oncogene polymorphism is found in a high number of endocrine tumor patients. Hum Genet; 2005 Jul;117(2-3):143-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, the presence of a 3'-terminally truncated RET proto-oncogene mRNA variant in benign and malignant thyroid neoplasias, as well as in a pheochromocytoma, an ovarian carcinoma and a medullary thyroid carcinoma, is demonstrated.
  • Analysis of DNA derived from varying regions within individual anaplastic thyroid carcinomas revealed an allele 1/allele 2 switch of the RFLP banding pattern, indicating loss of heterozygosity at the RET proto-oncogene locus.
  • [MeSH-major] 3' Untranslated Regions / genetics. Endocrine Gland Neoplasms / genetics. Gene Expression Regulation, Neoplastic / genetics. Loss of Heterozygosity / genetics. Oncogene Proteins / genetics. Polymorphism, Restriction Fragment Length. Receptor Protein-Tyrosine Kinases / genetics

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Biochem. 1992;61:419-40 [1353951.001]
  • [Cites] Hum Genet. 1996 Mar;97(3):299-303 [8786068.001]
  • [Cites] Dev Biol. 2003 Feb 15;254(2):262-76 [12591246.001]
  • [Cites] Nature. 1994 Jan 27;367(6461):380-3 [8114940.001]
  • [Cites] Mol Cell Neurosci. 1999 May;13(5):313-25 [10356294.001]
  • [Cites] Oncogene. 1995 Nov 16;11(10):2039-45 [7478523.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] J Pathol. 1994 Mar;172(3):255-60 [8195928.001]
  • [Cites] Nucleic Acids Res. 1996 Jun 15;24(12):2288-94 [8710498.001]
  • [Cites] Nature. 1996 Jun 27;381(6585):785-9 [8657281.001]
  • [Cites] Oncogene. 1995 Apr 6;10(7):1377-83 [7731689.001]
  • [Cites] Oncogene. 1999 Jul 1;18(26):3919-22 [10445857.001]
  • [Cites] J Mol Med (Berl). 2003 Jul;81(7):411-9 [12811413.001]
  • [Cites] Science. 1995 Jan 20;267(5196):381-3 [7824936.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):2845-9 [10850426.001]
  • [Cites] Nature. 1996 Jun 27;381(6585):789-93 [8657282.001]
  • [Cites] Oncogene. 2000 Jul 13;19(30):3445-8 [10918602.001]
  • [Cites] Oncogene. 1988 Nov;3(5):571-8 [3078962.001]
  • [Cites] Nat Genet. 2002 Apr;30(4):430-5 [11912494.001]
  • [Cites] Nature. 1994 Jan 27;367(6461):377-8 [8114938.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2979-85 [8187085.001]
  • [Cites] Biochem Biophys Res Commun. 1988 Jun 30;153(3):1290-5 [3390185.001]
  • [Cites] Hum Genet. 1995 Jul;96(1):27-32 [7607650.001]
  • [Cites] Nucleic Acids Res. 1990 Dec 25;18(24):7472 [1979682.001]
  • [Cites] Oncogene. 1990 Jan;5(1):97-102 [2181380.001]
  • [Cites] Biochimie. 1999 Apr;81(4):397-402 [10401675.001]
  • [Cites] Oncogene. 1999 Feb 11;18(6):1369-73 [10022819.001]
  • [Cites] Oncogene. 1993 Sep;8(9):2575-82 [8361767.001]
  • [Cites] Nature. 1994 Jan 27;367(6461):375-6 [7906866.001]
  • [Cites] Cell. 1990 Feb 23;60(4):557-63 [2406025.001]
  • [Cites] J Cell Physiol. 2003 May;195(2):168-86 [12652644.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):525-30 [9467569.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):380-93 [10458257.001]
  • [Cites] Cell. 1985 Jun;41(2):349-59 [2580642.001]
  • [Cites] Int J Oncol. 2003 Oct;23(4):1025-32 [12963982.001]
  • [Cites] Oncogene. 1990 Oct;5(10):1595-8 [1701232.001]
  • [Cites] Adv Anat Pathol. 2001 Nov;8(6):345-54 [11707626.001]
  • [Cites] Oncogene. 2000 Nov 20;19(49):5590-7 [11114739.001]
  • (PMID = 15841388.001).
  • [ISSN] 0340-6717
  • [Journal-full-title] Human genetics
  • [ISO-abbreviation] Hum. Genet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 3' Untranslated Regions; 0 / Oncogene Proteins; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  •  go-up   go-down


61. Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A: Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer; 2005 Apr 1;103(7):1330-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors.
  • BACKGROUND: Anaplastic thyroid carcinoma (ATC) is rare but is one of the most aggressive human malignancies.
  • Several prognostic factors have been observed in patients with ATC, and some experts advocate aggressive multimodal therapy in selected patients.
  • The authors analyzed prognostic factors and treatment outcomes in patients with ATC reported in the National Cancer Institute's Surveillance, Epidemiology, and End Results data base.
  • METHODS: The cohort consisted of 516 patients with ATC reported to 12 population-based cancer registries between 1973 and 2000.
  • RESULTS: The mean patient age at diagnosis was 71.3 years, and there were 171 men and 345 women.
  • CONCLUSIONS: Although most patients with ATC had an extremely poor prognosis, patients < 60 years old with intrathyroidal tumors survived longer.
  • Surgical resection with external beam radiotherapy for ATC was associated with lower cause-specific mortality.
  • [MeSH-major] Carcinoma / mortality. Thyroid Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 15739211.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


62. Takano H, Shibamoto T, Zhang W, Kurata Y: Liver volume, as assessed by four ultrasonic crystals arranged to form a tetrahedron, decreases during anaphylactic shock in anesthetized rats. Shock; 2010 Dec;34(6):586-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The measured relative change of the tetrahedron volume (V[utc]; percentage changes of the initial volume) was closely correlated with the liver weight change (W; percentage changes of the initial liver weight): V(utc) = 0.85W - 4.11 (r² = 0.67).

  • MedlinePlus Health Information. consumer health - Anaphylaxis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20351625.001).
  • [ISSN] 1540-0514
  • [Journal-full-title] Shock (Augusta, Ga.)
  • [ISO-abbreviation] Shock
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


63. Swaak-Kragten AT, de Wilt JH, Schmitz PI, Bontenbal M, Levendag PC: Multimodality treatment for anaplastic thyroid carcinoma--treatment outcome in 75 patients. Radiother Oncol; 2009 Jul;92(1):100-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality treatment for anaplastic thyroid carcinoma--treatment outcome in 75 patients.
  • PURPOSE: To retrospectively analyze the outcome of patients with anaplastic thyroid carcinoma (ATC) treated in the Erasmus MC.
  • MATERIAL AND METHODS: Seventy-five ATC-patients were treated between 1972 and 2003.
  • CONCLUSION: Despite the ultimately dismal prognosis of ATC-patients, multimodality treatment significantly improved local control and improved the median survival.
  • [MeSH-major] Carcinoma / therapy. Neoplasm Recurrence, Local. Thyroid Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19328572.001).
  • [ISSN] 1879-0887
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


64. Aukerman DF, Aukerman MM, Browning D: Medical coverage of high school athletics in North Carolina. South Med J; 2006 Feb;99(2):132-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary objective of this cross-sectional study was to assess the quality and extent of medical coverage at high school athletic events in North Carolina.
  • METHODS: A questionnaire, mailed to all athletic directors at public and private North Carolina high school members of the North Carolina High School Athletic Association, was used to assess medical coverage.
  • RESULTS: Only 56% of the schools had coverage by either nationally or state certified athletic trainers.
  • Although 71% of schools had physician coverage at some athletic events, less than 10% of physician coverage included monitoring of athletic practices.
  • Only 27% of the schools surveyed felt that their existing medical coverage of athletic events could be considered adequate.
  • [MeSH-major] Athletic Injuries. Emergency Medical Services. Health Services Needs and Demand / statistics & numerical data. School Health Services / statistics & numerical data


65. Fontana GA: Downregulation of cough by exercise and voluntary hyperpnea. Lung; 2010 Jan;188 Suppl 1:S95-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The intensity of the urge-to-cough (UTC), a cognitive component of coughing, was also recorded throughout the trials.
  • The log-log relationship between inhaled fog concentrations and the correspondingly evoked UTC values, an index of the perceptual magnitude of the UTC sensitivity, was also calculated.
  • With exercise and VIH compared with control, mean UTC values at cough threshold were not significantly changed: control, 3.83 +/- 1.11 cm; exercise, 3.12 +/- 0.82 cm; VIH, 4.08 +/- 1.67 cm.
  • Since the slopes of the log fog concentration/log UTC value were approximately halved during exercise and VIH compared with control, the UTC sensitivity to fog was depressed (p < 0.01).


66. Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, Wang Y, Trink A, El-Naggar AK, Tallini G, Vasko V, Xing M: Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res; 2007 Feb 15;13(4):1161-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer.
  • PURPOSE: To investigate the overall occurrence and relationship of genetic alterations in the phosphatidylinositol 3-kinase (PI3K)/Akt pathway in thyroid tumors and explore the scope of this pathway as a therapeutic target for thyroid cancer.
  • EXPERIMENTAL DESIGN: We examined collectively the major genetic alterations and their relationship in this pathway, including PIK3CA copy number gain and mutation, Ras mutation, and PTEN mutation, in a large series of primary thyroid tumors.
  • RESULTS: Occurrence of any of these genetic alterations was found in 25 of 81 (31%) benign thyroid adenoma (BTA), 47 of 86 (55%) follicular thyroid cancer (FTC), 21 of 86 (24%) papillary thyroid cancer (PTC), and 29 of 50 (58%) anaplastic thyroid cancer (ATC), with FTC and ATC most frequently harboring these genetic alterations.
  • A mutual exclusivity among these genetic alterations was seen in BTA, FTC, and PTC, suggesting an independent role of each of them through the PI3K/Akt pathway in the tumorigenesis of the differentiated thyroid tumors.
  • However, coexistence of these genetic alterations was increasingly seen with progression from differentiated tumor to undifferentiated ATC.
  • Their coexistence with BRAF mutation was also frequent in PTC and ATC.
  • CONCLUSIONS: The data provide strong genetic implication that aberrant activation of PI3K/Akt pathway plays an extensive role in thyroid tumorigenesis, particularly in FTC and ATC, and promotes progression of BTA to FTC and to ATC as the genetic alterations of this pathway accumulate.
  • Progression of PTC to ATC may be facilitated by coexistence of PI3K/Akt pathway-related genetic alterations and BRAF mutation.
  • The PI3K/Akt pathway may thus be a major therapeutic target in thyroid cancers.
  • [MeSH-major] Oncogene Protein v-akt / genetics. Phosphatidylinositol 3-Kinases / genetics. Thyroid Neoplasms / enzymology. Thyroid Neoplasms / genetics

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317825.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R0-1 CA113507-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human; EC 2.7.11.1 / Oncogene Protein v-akt; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


67. Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI: Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab; 2008 Jan;93(1):278-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer.
  • CONTEXT: Anaplastic thyroid carcinoma (ATC) can occur in the setting of differentiated thyroid carcinoma (DTC), which suggests a continuum in malignant progression from DTC to ATC.
  • The Ras/Raf-MAPK and the phosphatidylinositol 3-kinase/Akt signaling pathways play critical roles in DTC tumorigenesis, but their roles in the pathogenesis of ATC are poorly defined.
  • OBJECTIVE: Our objective was to explore the potential contributions of these two pathways in ATC pathogenesis.
  • DESIGN, SETTING, AND SUBJECTS: The mutational status of BRAF, PIK3CA, PTEN, and RAS genes was analyzed in genomic DNA from microdissected tumor specimens of 36 cases of ATC, and in 16 samples of paired-matched lymph node metastases.
  • We performed immunohistochemistry for phospho-ERK and phospho-AKT in 26 cases of ATC.
  • BRAF V600E mutation was identified in nine of 36 (25%) ATCs; seven cases had identical mutations in both the ATC and DTC components.
  • PIK3CA kinase domain mutations were found in five (14%) ATCs, one of which had mutations in both differentiated and anaplastic areas.
  • PIK3CA alterations occur preferentially in the later stages of ATC and were the most relevant events during thyroid cancer progression.
  • The activation of both pathways suggests an important role in ATC dedifferentiation.
  • [MeSH-major] Carcinoma / enzymology. MAP Kinase Signaling System / genetics. Mutation. Phosphatidylinositol 3-Kinases / metabolism. Thyroid Neoplasms / enzymology. raf Kinases / metabolism


68. Mulder H, Heerdink ER, van Iersel EE, Wilmink FW, Egberts AC: Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study. Ann Pharmacother; 2007 Mar;41(3):408-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In total, 416 drugs metabolized by CYP2D6 were prescribed, with 257 (62%) of these classified as an antidepressant (Anatomical and Therapeutic Chemical [ATC] category N06A) or antipsychotic (ATC N05A).

  • MedlinePlus Health Information. consumer health - Antidepressants.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17341534.001).
  • [ISSN] 1542-6270
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidepressive Agents; 0 / Antipsychotic Agents; EC 1.14.14.1 / Cytochrome P-450 CYP2D6
  •  go-up   go-down


69. Sofiadis A, Tani E, Foukakis T, Kjellman P, Skoog L, Höög A, Wallin G, Zedenius J, Larsson C: Diagnostic and prognostic potential of MIB-1 proliferation index in thyroid fine needle aspiration biopsy. Int J Oncol; 2009 Aug;35(2):369-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic and prognostic potential of MIB-1 proliferation index in thyroid fine needle aspiration biopsy.
  • Fine needle aspiration biopsy (FNAB) is the preferred technique for the initial diagnostic evaluation of thyroid lesions, which nevertheless poses a diagnostic challenge for all clinicians involved.
  • The latter necessitates the use of molecular markers on thyroid cytology.
  • In this study, we assessed whether MIB-1 proliferation index adds diagnostic information to the conventional cytological analysis of thyroid nodules and prognostic information in thyroid cancers.
  • MIB-1 index for various thyroid lesions was retrospectively reviewed in a series of 504 patients.
  • Furthermore, the prognostic value of MIB-1 index was investigated for 183 of the patients with papillary thyroid cancer (PTC).
  • MIB-1 index was significantly higher in anaplastic thyroid cancer (ATC) compared to other tumor types (p<0.01).
  • No significant difference in MIB-1 index was observed between thyroid adenomas and follicular carcinomas.
  • In PTC, MIB-1 index equal to or >4% was found to be an independent factor significantly associated with higher risk of distant metastasis and disease-related mortality (p<0.05).
  • Conclusively, this study shows that preoperative MIB-1 index assessment in FNAB of thyroid nodules offers little diagnostic information as far as follicular tumors are concerned.
  • In cases of PTC, though, MIB-1 may serve as a prognostic indicator of disease spreading and poor survival and hence influence the planning of the overall treatment scheme.
  • [MeSH-major] Antibodies, Antinuclear / immunology. Antibodies, Monoclonal / immunology. Ki-67 Antigen / analysis. Thyroid Gland / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Needle. Carcinoma, Papillary / pathology. Cell Proliferation. Child. Female. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19578751.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / Ki-67 Antigen; 0 / MIB-1 antibody
  •  go-up   go-down


70. Weidner TG, Henning JM: Importance and applicability of approved clinical instructor standards and criteria to certified athletic trainers in different clinical education settings. J Athl Train; 2005 Oct-Dec;40(4):326-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Importance and applicability of approved clinical instructor standards and criteria to certified athletic trainers in different clinical education settings.
  • CONTEXT: For optimal clinical education of athletic training students, Clinical Instructor Educators and program directors need to proactively select, train, and evaluate their Approved Clinical Instructors (ACIs).
  • OBJECTIVE: To assess the relative importance and applicability of ACI standards to certified athletic trainers employed in different athletic training clinical education settings.
  • CONCLUSIONS: The Weidner and Henning standards are considered to be important and applicable across a variety of athletic training clinical education settings.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16404455.001).
  • [ISSN] 1062-6050
  • [Journal-full-title] Journal of athletic training
  • [ISO-abbreviation] J Athl Train
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1323295
  •  go-up   go-down


71. Haberthür C, Guttmann J: Short-term effects of positive end-expiratory pressure on breathing pattern: an interventional study in adult intensive care patients. Crit Care; 2005 Aug;9(4):R407-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In 30 tracheally intubated, spontaneously breathing patients, we sequentially applied PEEP to the trachea at 0, 5 and 10 cmH2O, and then again at 5 cmH2O for 30 s each, using the automatic tube compensation mode.
  • Post hoc analysis revealed a similar but stronger response in patients with impaired respiratory system compliance.

  • MedlinePlus Health Information. consumer health - Critical Care.
  • Hazardous Substances Data Bank. Carbon dioxide .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Respir Crit Care Med. 2000 Nov;162(5):1633-40 [11069788.001]
  • [Cites] Am J Respir Crit Care Med. 1999 Sep;160(3):950-60 [10471624.001]
  • [Cites] J Appl Physiol (1985). 2001 Jun;90(6):2330-40 [11356800.001]
  • [Cites] Crit Care Med. 2003 Nov;31(11):2619-26 [14605533.001]
  • [Cites] Technol Health Care. 2003;11(6):413-24 [14757920.001]
  • [Cites] Br Med J. 1974 Jun 22;2(5920):656-9 [4835444.001]
  • [Cites] J Appl Physiol. 1975 May;38(5):869-74 [1126897.001]
  • [Cites] J Appl Physiol. 1975 Mar;38(3):474-80 [168175.001]
  • [Cites] J Pediatr. 1977 Jun;90(6):976-81 [323448.001]
  • [Cites] Respir Physiol. 1981 Sep;45(3):343-55 [6800008.001]
  • [Cites] Am J Physiol. 1986 May;250(5 Pt 2):R902-9 [3706575.001]
  • [Cites] Respir Physiol. 1988 Aug;73(2):145-54 [3420318.001]
  • [Cites] J Appl Physiol (1985). 1990 Mar;68(3):1092-100 [2140347.001]
  • [Cites] J Appl Physiol (1985). 1991 Aug;71(2):474-80 [1938718.001]
  • [Cites] Pediatr Pulmonol. 1991;11(4):345-9 [1758760.001]
  • [Cites] J Appl Physiol (1985). 1992 Mar;72(3):881-7 [1533214.001]
  • [Cites] J Appl Physiol (1985). 1992 Aug;73(2):479-85 [1399969.001]
  • [Cites] Anesthesiology. 1993 Sep;79(3):503-13 [8363076.001]
  • [Cites] Respir Physiol. 1993 Aug;93(2):175-87 [8210757.001]
  • [Cites] Respir Med. 1996 Sep;90(8):463-6 [8869439.001]
  • [Cites] Am J Respir Crit Care Med. 1996 Oct;154(4 Pt 1):938-44 [8887589.001]
  • [Cites] J Appl Physiol (1985). 1998 Dec;85(6):2033-9 [9843523.001]
  • [Cites] Intensive Care Med. 1999 May;25(5):514-9 [10401948.001]
  • [Cites] Respiration. 2001;68(2):140-4 [11287827.001]
  • (PMID = 16137354.001).
  • [ISSN] 1466-609X
  • [Journal-full-title] Critical care (London, England)
  • [ISO-abbreviation] Crit Care
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 142M471B3J / Carbon Dioxide
  • [Other-IDs] NLM/ PMC1269457
  •  go-up   go-down


72. Métayé T, Levillain P, Kraimps JL, Perdrisot R: Immunohistochemical detection, regulation and antiproliferative function of G-protein-coupled receptor kinase 2 in thyroid carcinomas. J Endocrinol; 2008 Jul;198(1):101-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection, regulation and antiproliferative function of G-protein-coupled receptor kinase 2 in thyroid carcinomas.
  • TSH, via its G-protein-coupled receptor, activates cell growth of both benign and malignant thyroid tumors.
  • G-protein-coupled receptors (GR) kinase 2 (GRK2) has been reported to regulate the TSH receptor but its role in cancer is unknown.
  • To determine a possible function for GRK2 in the growth process of thyroid cancers, we analysed its expression in normal and tumoral thyroid tissues and studied thyroid cancer cell line proliferation after GRK2 overexpression.
  • Thirty one thyroid tissues, including 16 non-medullary thyroid cancers and 15 adjacent normal tissues, were analysed by immunohistochemistry.
  • Immunohistochemical staining showed an increase in GRK2 in thyroid cancers including papillary, follicular, and anaplastic types, compared with their adjacent normal tissues.
  • TSH and TSH in association with insulin or IGF-I stimulated GRK2 protein accumulation in normal human thyroid cells in primary culture.
  • After GRK2 overexpression in two poorly differentiated thyroid cell lines, all the clones showed a significant reduction in cell proliferation, ranging from 28 to 65% inhibition compared with vector alone after 96-h culture.
  • In conclusion, thyroid mitogenic factor-stimulated GRK2 accumulation may explain, in part, high GRK2 levels in differentiated carcinoma, because TSH, insulin, or IGF-I is known to be involved in the thyroid cancer progression.
  • Surprisingly, instead of stimulating, GRK2 reduced cell proliferation revealing a new role for this kinase in the growth of thyroid cancers.
  • [MeSH-major] G-Protein-Coupled Receptor Kinase 2 / analysis. G-Protein-Coupled Receptor Kinase 2 / metabolism. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Aged. Blotting, Western. Cell Proliferation. Cells, Cultured. Cyclic AMP / metabolism. Female. Humans. Immunohistochemistry. Male. Middle Aged. Thyroid Gland / chemistry. Thyrotropin / pharmacology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18451066.001).
  • [ISSN] 1479-6805
  • [Journal-full-title] The Journal of endocrinology
  • [ISO-abbreviation] J. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 9002-71-5 / Thyrotropin; E0399OZS9N / Cyclic AMP; EC 2.7.11.15 / G-Protein-Coupled Receptor Kinase 2
  •  go-up   go-down


73. Zhang C, Huang Y: Complete mitochondrial genome of Oxya chinensis (Orthoptera, Acridoidea). Acta Biochim Biophys Sin (Shanghai); 2008 Jan;40(1):7-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The initiation codon of the cytochrome oxidase subunit I gene in the mitochondrial genome of O. chinensis appears to be ATC, instead of the tetranucleotides that have been reported in Locusta migratoria (L. migratoria) mitochondrial genome.
  • [MeSH-major] DNA, Mitochondrial / genetics. Genome / genetics. Mitochondria / genetics. Orthoptera / classification. Orthoptera / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18180849.001).
  • [ISSN] 1745-7270
  • [Journal-full-title] Acta biochimica et biophysica Sinica
  • [ISO-abbreviation] Acta Biochim. Biophys. Sin. (Shanghai)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Mitochondrial
  •  go-up   go-down


74. Pohjanoksa-Mäntylä MK, Antila J, Eerikäinen S, Enäkoski M, Hannuksela O, Pietilä K, Airaksinen M: Utilization of a community pharmacy-operated national drug information call center in Finland. Res Social Adm Pharm; 2008 Jun;4(2):144-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority (83%) of these calls were therapeutic or pharmaceutical inquiries, with 26% concerning costs and reimbursements, 14% interactions, 14% dosages, and 11% adverse effects.
  • Nervous system drugs (Anatomical Therapeutic Chemical [ATC] classification N), anti-infectives (J), and musculoskeletal drugs (M) accounted for 20%, 18%, and 13% of the calls, respectively.
  • Nonsteroidal anti-inflammatory drugs (NSAID) (9% of the calls), antidepressants (6%), and penicillin (5%) were the most often inquired about ATC-subgroups.
  • This may especially be the case for certain population groups, and in regard to nervous system drugs, anti-infectives and NSAID.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18555967.001).
  • [ISSN] 1551-7411
  • [Journal-full-title] Research in social & administrative pharmacy : RSAP
  • [ISO-abbreviation] Res Social Adm Pharm
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


75. Perrier E, Manen O, Cinquetti G: Essential thrombocytosis and myocardial infarction in an aircrew member: aeromedical concerns. Aviat Space Environ Med; 2006 Jan;77(1):69-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report on the case of a 40-yr-old, female French military air traffic controller (ATC) admitted for an ST-elevation myocardial infarction.
  • The diagnosis of ET was then established.
  • No platelet-lowering therapy was prescribed, aspirin was continued, and this ATC was considered unfit for operational duties.
  • [MeSH-major] Military Personnel. Myocardial Infarction / etiology. Thrombocytosis / diagnosis. Work Capacity Evaluation
  • [MeSH-minor] Adult. Aerospace Medicine. Aspirin / therapeutic use. Coronary Angiography. Coronary Thrombosis / radiography. Coronary Thrombosis / therapy. Female. Humans. Platelet Aggregation Inhibitors / therapeutic use. Smoking

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • MedlinePlus Health Information. consumer health - Veterans and Military Health.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16422458.001).
  • [ISSN] 0095-6562
  • [Journal-full-title] Aviation, space, and environmental medicine
  • [ISO-abbreviation] Aviat Space Environ Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Platelet Aggregation Inhibitors; R16CO5Y76E / Aspirin
  •  go-up   go-down


76. Schweppe RE, Kerege AA, French JD, Sharma V, Grzywa RL, Haugen BR: Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer. J Clin Endocrinol Metab; 2009 Jun;94(6):2199-203
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer.
  • CONTEXT: Focal adhesion kinase (FAK) and Src are overexpressed and activated in many cancers and have been associated with tumor progression.
  • The role of the Src-FAK complex has not been characterized in papillary and anaplastic thyroid cancer (PTC and ATC).
  • OBJECTIVE: The goal of this study was to determine the role of Src and FAK in the growth and invasion of PTC and ATC.
  • DESIGN: PTC and ATC cells were treated with the oral Src inhibitor, AZD0530, to determine the consequences of Src inhibition using growth and invasion assays.
  • RESULTS: AZD0530 treatment inhibited the growth and invasion in four of five thyroid cancer cell lines, and inhibition did not correlate with basal levels of phospho-Src.
  • Instead, we show for the first time that FAK, a critical substrate and effector of Src, is phosphorylated at tyrosine residue 861 (pY861) in PTC and ATC cells, and high levels of phospho-FAK correlate with AZD0530 sensitivity.
  • CONCLUSIONS: Inhibition of the Src-FAK complex represents a promising therapeutic strategy for patients with advanced thyroid cancer, and phospho-FAK represents a potential biomarker for response.

  • Genetic Alliance. consumer health - Thyroid cancer, anaplastic.
  • Genetic Alliance. consumer health - Thyroid cancer, papillary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2000 Nov 20;19(49):5636-42 [11114744.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Nov;93(11):4331-41 [18713817.001]
  • [Cites] J Korean Med Sci. 2004 Oct;19(5):710-5 [15483349.001]
  • [Cites] J Biol Chem. 1999 Apr 9;274(15):10566-70 [10187851.001]
  • [Cites] Surgery. 2004 Dec;136(6):1212-7 [15657578.001]
  • [Cites] Surgery. 2005 Aug;138(2):269-74 [16153436.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10199-207 [16288007.001]
  • [Cites] Cancer Cell. 2006 Jan;9(1):4-6 [16413465.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1623-9 [16533790.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1785-93 [16551863.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1136-44 [16731745.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6521-9 [16818623.001]
  • [Cites] J Med Chem. 2006 Nov 2;49(22):6465-88 [17064066.001]
  • [Cites] Br J Cancer. 2007 Jan 15;96(1):16-20 [17179987.001]
  • [Cites] Biochem Pharmacol. 2007 Mar 1;73(5):597-609 [16997283.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1161-70 [17317825.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2800-8 [17363602.001]
  • [Cites] Ann Oncol. 2007 Nov;18(11):1765-73 [17426060.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7232-6 [18094400.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2358-62 [18258742.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3323-33 [18451159.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Jun;93(6):2194-201 [18381570.001]
  • [Cites] Methods. 2003 Jul;30(3):256-68 [12798140.001]
  • (PMID = 19293266.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA100560; United States / NCI NIH HHS / CA / P30 CA 046934; United States / NCI NIH HHS / CA / P30 CA046934; United States / NCI NIH HHS / CA / R01 CA100560; United States / NCI NIH HHS / CA / K12 CA086913
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzodioxoles; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 9KD24QGH76 / saracatinib; EC 2.7.10.2 / Focal Adhesion Protein-Tyrosine Kinases; EC 2.7.10.2 / Proto-Oncogene Proteins pp60(c-src)
  • [Other-IDs] NLM/ PMC2690419
  •  go-up   go-down


77. Kondo T, Nakazawa T, Ma D, Niu D, Mochizuki K, Kawasaki T, Nakamura N, Yamane T, Kobayashi M, Katoh R: Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas. Lab Invest; 2009 Jul;89(7):791-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas.
  • Thyroid transcription factor-1 (TTF-1), also known as NKX2-1, is a homeodomain containing transcriptional factor identified in thyroid, lung and central nervous system.
  • In the thyroid, TTF-1 is essential for thyroid organogenesis and governs thyroid functions by regulating various thyroid-specific genes.
  • We previously demonstrated that most differentiated thyroid neoplasms, including follicular adenomas/carcinomas and papillary carcinomas, express TTF-1 at both protein and mRNA levels.
  • However, certain subtypes of thyroid cancers have shown low or negative expression of TTF-1.
  • The aim of our study was to investigate the function of epigenetic modification in dysregulation of TTF-1 in thyroid carcinoma cells.
  • We evaluated the expression of TTF-1 in primary thyroid tissues (normal thyroid, papillary carcinoma and undifferentiated carcinoma) and in thyroid carcinoma cell lines using immunohistochemistry and RT-PCR.
  • We also explored whether epigenetic modifiers, including 5-aza-deoxycytidine, could restore TTF-1 expression in thyroid carcinoma cells.
  • In our current study, immunohistochemistry and RT-PCR showed positive expression of TTF-1 in normal thyroids and papillary carcinomas.
  • Meanwhile, most of the undifferentiated carcinomas and the cell lines lost TTF-1 expression.
  • No methylation in the CpG of TTF-1 promoter was detected in normal thyroids or papillary carcinomas.
  • In contrast, DNA methylation was identified in 60% of the undifferentiated carcinomas (6/10) and 50% of the cell lines (4/8).
  • ChIP assay demonstrated that acetylation of H3-lys9 was positively correlated with TTF-1 expression in thyroid carcinoma cells.
  • Finally, DNA demethylating agents could restore TTF-1 gene expression in the thyroid carcinoma cell lines.
  • Our data suggest that epigenetics is involved with inactivation of TTF-1 in thyroid carcinomas, and provide a possible means of using TTF-1 as a target for differentiation-inducing therapy through epigenetic modification.
  • [MeSH-major] DNA Methylation. Gene Silencing. Histones / metabolism. Nuclear Proteins / genetics. Thyroid Neoplasms / genetics. Thyroid Neoplasms / metabolism. Transcription Factors / genetics
  • [MeSH-minor] Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Base Sequence. Carcinoma, Papillary / etiology. Carcinoma, Papillary / genetics. Carcinoma, Papillary / metabolism. Cell Line, Tumor. Chromatin Immunoprecipitation. CpG Islands. DNA Primers / genetics. Epigenesis, Genetic / drug effects. Gene Expression Profiling. Humans. Hydroxamic Acids / pharmacology. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Thyroid Gland / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19506552.001).
  • [ISSN] 1530-0307
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Histones; 0 / Hydroxamic Acids; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 3X2S926L3Z / trichostatin A; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  •  go-up   go-down


78. Kopjar N, Zeljezić D, Kasuba V, Rozgaj R: [Antineoplastic drugs as a potential risk factor in occupational settings: mechanisms of action at the cell level, genotoxic effects, and their detection using different biomarkers]. Arh Hig Rada Toksikol; 2010 Mar;61(1):121-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Classification of antineoplastic drugs according to the IARC monographs on the evaluation of carcinogenic risks to humans is accompanied by data on their mutagenicity and the most recent updates in the Anatomical Therapeutic Chemical (ATC) Classification System.

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20338875.001).
  • [ISSN] 0004-1254
  • [Journal-full-title] Arhiv za higijenu rada i toksikologiju
  • [ISO-abbreviation] Arh Hig Rada Toksikol
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 212
  •  go-up   go-down


79. Lin D, Ippolito GC, Zong RT, Bryant J, Koslovsky J, Tucker P: Bright/ARID3A contributes to chromatin accessibility of the immunoglobulin heavy chain enhancer. Mol Cancer; 2007 Mar 26;6:23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bright positively activates IgH transcriptional initiation by binding to ATC-rich P sites within nuclear matrix attachment regions (MARs) flanking the IgH intronic enhancer (Emu).
  • A system was established in which VH promoter-driven in vitro transcription on chromatin- reconstituted templates was responsive to Emu.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 1991 Oct;11(10):5206-11 [1922040.001]
  • [Cites] Mol Cell Biol. 1991 Oct;11(10):5197-205 [1922039.001]
  • [Cites] Science. 1993 Jul 2;261(5117):82-6 [8316859.001]
  • [Cites] Genes Dev. 1993 Oct;7(10):2016-32 [8406005.001]
  • [Cites] Science. 1994 Aug 26;265(5176):1221-5 [8066460.001]
  • [Cites] J Immunol. 1995 Nov 1;155(9):4270-7 [7594585.001]
  • [Cites] Genes Dev. 1995 Dec 15;9(24):3067-82 [8543152.001]
  • [Cites] J Biol Chem. 1996 Oct 4;271(40):25041-8 [8798787.001]
  • [Cites] EMBO J. 1996 Sep 16;15(18):5014-21 [8890174.001]
  • [Cites] Nature. 1997 Jan 16;385(6613):269-72 [9000077.001]
  • [Cites] Mol Cell Biol. 1997 May;17(5):2658-68 [9111336.001]
  • [Cites] Mol Cell Biol. 1997 Jul;17(7):3527-35 [9199288.001]
  • [Cites] J Immunol. 1998 May 15;160(10):4747-54 [9590220.001]
  • [Cites] Mol Cell Biol. 1998 Jun;18(6):3596-603 [9584200.001]
  • [Cites] Mol Cell Biol. 1998 Sep;18(9):5121-7 [9710596.001]
  • [Cites] J Biol Chem. 1999 Feb 19;274(8):4858-62 [9988726.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1526-31 [9990057.001]
  • [Cites] J Biol Chem. 1999 May 28;274(22):15633-45 [10336460.001]
  • [Cites] Methods Enzymol. 1999;304:399-414 [10372373.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1998;63:515-24 [10384316.001]
  • [Cites] Immunity. 1999 Jul;11(1):11-20 [10435575.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3741-7 [10446990.001]
  • [Cites] Mol Cell Biol. 1999 Oct;19(10):6632-41 [10490602.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2834-42 [15728493.001]
  • [Cites] Mol Cell Biol. 2005 Mar;25(6):2073-84 [15743806.001]
  • [Cites] Genomics. 2005 Aug;86(2):242-51 [15922553.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 4;102(40):14362-7 [16186486.001]
  • [Cites] Mol Cell Biol. 2006 Mar;26(6):2187-201 [16507996.001]
  • [Cites] Mol Cell Biol. 2006 Jun;26(12):4758-68 [16738337.001]
  • [Cites] Science. 1994 Sep 9;265(5178):1573-7 [8079170.001]
  • [Cites] Genes Dev. 1994 Oct 15;8(20):2453-65 [7958909.001]
  • [Cites] Mol Cell Biol. 1995 Jun;15(6):3217-26 [7760817.001]
  • [Cites] Genes Dev. 1999 Nov 15;13(22):3003-14 [10580007.001]
  • [Cites] Crit Rev Eukaryot Gene Expr. 1999;9(3-4):295-310 [10651246.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Cell. 2000 Mar 31;101(1):79-89 [10778858.001]
  • [Cites] EMBO J. 2000 Aug 1;19(15):4123-33 [10921892.001]
  • [Cites] Mol Cell Biol. 2001 Jan;21(1):196-208 [11113195.001]
  • [Cites] Trends Biochem Sci. 2001 Jan;26(1):7-9 [11165500.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1999;64:99-107 [11232342.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1999;64:109-18 [11232275.001]
  • [Cites] Mol Cell Biol. 2001 Apr;21(8):2918-32 [11283269.001]
  • [Cites] J Biol Chem. 2001 Jun 15;276(24):21325-30 [11294836.001]
  • [Cites] EMBO J. 2001 Nov 15;20(22):6394-403 [11707410.001]
  • [Cites] Nat Cell Biol. 2002 Feb;4(2):148-53 [11812999.001]
  • [Cites] J Immunol. 2002 Sep 1;169(5):2477-87 [12193717.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15030-5 [12415115.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11577-82 [14500909.001]
  • [Cites] J Biol Chem. 2003 Oct 24;278(43):42106-14 [12907668.001]
  • [Cites] Mol Immunol. 2004 Jan;40(10):723-31 [14644098.001]
  • [Cites] J Biomol NMR. 2004 Apr;28(4):357-67 [14872127.001]
  • [Cites] Immunol Rev. 2004 Aug;200:182-96 [15242405.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 May;79(9):2996-3000 [6806821.001]
  • [Cites] Nucleic Acids Res. 1983 Mar 11;11(5):1475-89 [6828386.001]
  • [Cites] Nature. 1986 Oct 9-15;323(6088):548-51 [3093895.001]
  • [Cites] J Biol Chem. 1987 Apr 15;262(11):5394-7 [3031052.001]
  • [Cites] Mol Cell Biol. 1987 Jul;7(7):2558-67 [3039350.001]
  • [Cites] Genes Dev. 1988 Oct;2(10):1227-37 [3264542.001]
  • [Cites] Genes Dev. 1989 Aug;3(8):1255-66 [2792763.001]
  • [Cites] Mol Cell Biol. 1990 Mar;10(3):982-90 [2304473.001]
  • [Cites] Nucleic Acids Res. 1990 May 11;18(9):2643-8 [2111008.001]
  • [Cites] EMBO J. 1993 Jun;12(6):2321-7 [8508765.001]
  • (PMID = 17386101.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / F32 CA110624; United States / NCI NIH HHS / CA / R01 CA031534; United States / NCI NIH HHS / CA / 1F32CA110624-01A1; United States / NCI NIH HHS / CA / CA31534
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ARID3A protein, human; 0 / Chromatin; 0 / DNA-Binding Proteins; 0 / Immunoglobulin Heavy Chains; 0 / Trans-Activators; 0 / Transcription Factors; EC 3.1.- / Deoxyribonucleases
  • [Other-IDs] NLM/ PMC1852116
  •  go-up   go-down


80. Sinorita H, Madiyan M, Pramono RB, Purnama LB, Ikhsan MR, Asdie AH: ACE gene insertion/deletion polymorphism among patients with type 2 diabetes, and its relationship with metabolic syndrome at Sardjito Hospital Yogyakarta, Indonesia. Acta Med Indones; 2010 Jan;42(1):12-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To determine the ACE genotype of the patients, a genomic DNA fragment on intron 16 of the ACE gene was amplified by polymerase chain reaction (PCR) using a forward primer 5'-CTG GAG ACC ACT CCC ATC CTT TCT-3' and reverse primer 5'-GAT GTG GCC ATC ACA RTC GTC AGA T-3'.


81. Cruciol-Souza JM, Thomson JC: Prevalence of potential drug-drug interactions and its associated factors in a Brazilian teaching hospital. J Pharm Pharm Sci; 2006;9(3):427-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Potential DDI were identified using DrugReax system.
  • Patient's age and gender, number of prescribers; number of drugs and therapeutic drug classes on prescriptions were explored as associated factors to DDI.
  • The rate of potential DDI was significantly associated to in-patients' gender [woman, Odds ratio (OR)=1.23 (P=0.035)], age=55 years old [OR=1.5 (P=0.0008)], number of therapeutic drug class (ATC code, level 1)=4 [OR=5.5 (P=0.0000), cardiology patients [OR=7.87 (P=0.0000)] hospitalized at weekends [OR=1.24 (P=0.039)] and having digoxin prescribed [OR=16.79 (P=0.0000)].
  • A positive correlation was found between DDI, patient's age, number of drugs and therapeutic action ATC codes were significant, controlling for gender (Pearson's r=0.628, P=0.001).

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17207423.001).
  • [ISSN] 1482-1826
  • [Journal-full-title] Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Société canadienne des sciences pharmaceutiques
  • [ISO-abbreviation] J Pharm Pharm Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  •  go-up   go-down


82. de Oliveira Martins S, Soares MA, Foppe van Mil JW, Cabrita J: Inappropriate drug use by Portuguese elderly outpatients--effect of the Beers criteria update. Pharm World Sci; 2006 Oct;28(5):296-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The drugs were distributed mainly in the following 3 ATC (Anatomical Therapeutic Chemical Classification) classes: C (cardiovascular system), N (nervous system) and A (alimentary tract).
  • According to the ATC Classification, more than one half of the cases of inappropriateness were related with long acting benzodiazepines and with ticlopidine.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Geriatr Soc. 2002 Jan;50(1):26-34 [12028243.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2002 Mar;11(2):127-34 [11998537.001]
  • [Cites] Ann Pharmacother. 2002 Mar;36(3):404-9 [11895051.001]
  • [Cites] Arch Intern Med. 1991 Sep;151(9):1825-32 [1888249.001]
  • [Cites] Pharmacotherapy. 2000 Feb;20(2):221-8 [10678301.001]
  • [Cites] Arch Intern Med. 2003 Dec 8-22;163(22):2716-24 [14662625.001]
  • [Cites] Age Ageing. 2000 Jan;29(1):35-9 [10690693.001]
  • [Cites] J Am Geriatr Soc. 2004 Nov;52(11):1934-9 [15507075.001]
  • [Cites] Int J Geriatr Psychiatry. 1999 Apr;14(4):280-4 [10340189.001]
  • [Cites] BMC Geriatr. 2004 Oct 15;4:9 [15488143.001]
  • [Cites] JAMA. 1998 Oct 14;280(14):1249-52 [9786375.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2004 Oct;13(10):669-82 [15386589.001]
  • [Cites] J Am Geriatr Soc. 1994 Dec;42(12):1241-7 [7983285.001]
  • [Cites] Arch Intern Med. 1997 Jul 28;157(14):1531-6 [9236554.001]
  • [Cites] Am J Geriatr Pharmacother. 2003 Dec;1(2):61-74 [15555468.001]
  • [Cites] Ann Pharmacother. 2001 Oct;35(10):1166-72 [11675839.001]
  • [Cites] J Am Geriatr Soc. 1997 Aug;45(8):945-8 [9256846.001]
  • [Cites] Arch Intern Med. 2000 Oct 9;160(18):2825-31 [11025793.001]
  • [Cites] Eur J Intern Med. 2003 Oct;14(6):372-376 [14769496.001]
  • [Cites] J Am Pharm Assoc (Wash). 2000 May-Jun;40(3):417-24 [10853543.001]
  • [Cites] Eur J Clin Pharmacol. 2004 May;60(3):217-20 [15069591.001]
  • [Cites] Ann Pharmacother. 2002 Nov;36(11):1675-81 [12398558.001]
  • [Cites] J Am Pharm Assoc (Wash). 2002 Nov-Dec;42(6):847-57 [12482007.001]
  • [Cites] CMAJ. 1997 Feb 1;156(3):385-91 [9033421.001]
  • [Cites] Am J Geriatr Pharmacother. 2003 Sep;1(1):38-43 [15555464.001]
  • [Cites] J Clin Epidemiol. 1992 Oct;45(10):1045-51 [1474400.001]
  • (PMID = 17111245.001).
  • [ISSN] 0928-1231
  • [Journal-full-title] Pharmacy world & science : PWS
  • [ISO-abbreviation] Pharm World Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


83. Song M, Park JE, Park SG, Lee DH, Choi HK, Park BC, Ryu SE, Kim JH, Cho S: NSC-87877, inhibitor of SHP-1/2 PTPs, inhibits dual-specificity phosphatase 26 (DUSP26). Biochem Biophys Res Commun; 2009 Apr 17;381(4):491-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since DUSP26 is involved in survival of anaplastic thyroid cancer (ATC) cells, NSC-87877 could be a therapeutic reagent for treating ATC.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19233143.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / NSC-87877; 0 / Quinolines; EC 3.1.3.- / Mitogen-Activated Protein Kinase Phosphatases; EC 3.1.3.48 / DUSP26 protein, human; EC 3.1.3.48 / Dual-Specificity Phosphatases; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 11; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 6
  •  go-up   go-down


84. Yano Y, Kamma H, Matsumoto H, Fujiwara M, Bando H, Hara H, Yashiro T, Ueno E, Ito K, Uchida K: Growth suppression of thyroid cancer cells by adenylcyclase activator. Oncol Rep; 2007 Aug;18(2):441-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth suppression of thyroid cancer cells by adenylcyclase activator.
  • Thyroid stimulating hormone (TSH) is known to increase intracytoplasmic cyclic adenosine monophosphate (cAMP) and to regulate the growth of normal follicular cells.
  • The aim of this study was to explore the role of the cAMP-mediated signaling pathway stimulated by TSH as a cell growth modulator in human thyroid cancer cells.
  • One papillary thyroid cancer cell line, K1 cells and two anaplastic thyroid cancer cell lines, TTA1 and TTA2 cells were treated with forskolin, which directly activates adenyl cyclase to raise the level of intracellular cAMP.
  • Forskolin suppressed thyroid cancer cell proliferations, especially in K1 cells, in a dose-dependent manner and induced growth arrest at the G0/G1 phase of the cell cycle.
  • In conclusion, we demonstrated that forskolin was involved in G1 arrest and MAPK activation in K1 thyroid cancer cells.
  • Our study suggests that the TSH signal mediated by cAMP acts as a negative regulator in thyroid cancer cells, unlike that in normal follicular cells.
  • [MeSH-minor] Blotting, Western. Cell Cycle / drug effects. Cell Line, Tumor. Dose-Response Relationship, Drug. Enzyme Activation / drug effects. Gene Expression Regulation, Neoplastic / drug effects. Hepatocyte Growth Factor / pharmacology. Humans. Insulin-Like Growth Factor I / pharmacology. MAP Kinase Signaling System / drug effects. Mitogen-Activated Protein Kinase Kinases / metabolism. Phosphorylation / drug effects. Receptors, Thyrotropin / genetics. Receptors, Thyrotropin / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Thyroid Neoplasms / metabolism. Thyroid Neoplasms / pathology. Time Factors

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17611668.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Receptors, Thyrotropin; 1F7A44V6OU / Colforsin; 67256-21-7 / Hepatocyte Growth Factor; 67763-96-6 / Insulin-Like Growth Factor I; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; EC 4.6.1.1 / Adenylyl Cyclases
  •  go-up   go-down


85. Zhang P, Martin PD, Purcarea C, Vaishnav A, Brunzelle JS, Fernando R, Guy-Evans HI, Evans DR, Edwards BF: Dihydroorotase from the hyperthermophile Aquifex aeolicus is activated by stoichiometric association with aspartate transcarbamoylase and forms a one-pot reactor for pyrimidine biosynthesis. Biochemistry; 2009 Feb 03;48(4):766-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In prokaryotes, the first three enzymes in pyrimidine biosynthesis, carbamoyl phosphate synthetase (CPS), aspartate transcarbamoylase (ATC), and dihydroorotase (DHO), are commonly expressed separately and either function independently (Escherichia coli) or associate into multifunctional complexes (Aquifex aeolicus).
  • In mammals the enzymes are expressed as a single polypeptide chain (CAD) in the order CPS-DHO-ATC and associate into a hexamer.
  • This study presents the three-dimensional structure of the noncovalent hexamer of DHO and ATC from the hyperthermophile A. aeolicus at 2.3 A resolution.
  • In the crystal structure, six DHO and six ATC chains form a hollow dodecamer, in which the 12 active sites face an internal reaction chamber that is approximately 60 A in diameter and connected to the cytosol by narrow tunnels.

  • Hazardous Substances Data Bank. OROTIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Genet. 2000 Jan;16(1):9-11 [10637623.001]
  • [Cites] Proteins. 1999 Dec 1;37(4):729-42 [10651286.001]
  • [Cites] Methods Enzymol. 2001;331:248-70 [11265467.001]
  • [Cites] Biochemistry. 2001 Jun 19;40(24):6989-97 [11401542.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10037-41 [11517324.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2001 Oct;57(Pt 10):1451-6 [11567159.001]
  • [Cites] Reproduction. 2002 Jun;123(6):757-68 [12052230.001]
  • [Cites] J Biol Chem. 2002 Jul 5;277(27):24490-8 [11959858.001]
  • [Cites] J Synchrotron Radiat. 2003 Jan 1;10(Pt 1):23-5 [12511787.001]
  • [Cites] Proteins. 2003;53 Suppl 6:491-6 [14579338.001]
  • [Cites] Curr Opin Struct Biol. 2003 Dec;13(6):665-73 [14675543.001]
  • [Cites] J Biol Chem. 2003 Dec 26;278(52):52924-34 [14534296.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33035-8 [15096496.001]
  • [Cites] Nature. 1968 Jun 22;218(5147):1119-21 [5656633.001]
  • [Cites] Arch Biochem Biophys. 1969 Nov;134(2):352-65 [4311178.001]
  • [Cites] Proc Natl Acad Sci U S A. 1975 May;72(5):1712-6 [168571.001]
  • [Cites] J Biol Chem. 1980 Dec 10;255(23):11372-80 [6108322.001]
  • [Cites] J Biol Chem. 1980 Dec 10;255(23):11381-95 [6108323.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Oct;82(20):6802-6 [2995985.001]
  • [Cites] Methods Enzymol. 1985;113:627-35 [3937019.001]
  • [Cites] J Mol Biol. 1985 Dec 20;186(4):715-24 [3912514.001]
  • [Cites] J Biol Chem. 1986 May 5;261(13):6073-83 [2871022.001]
  • [Cites] Science. 1988 Aug 5;241(4866):669-74 [3041592.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jan;86(1):46-50 [2643106.001]
  • [Cites] Trends Biochem Sci. 1990 Feb;15(2):53-9 [2186515.001]
  • [Cites] Science. 1992 Mar 20;255(5051):1544-50 [1549782.001]
  • [Cites] J Biol Chem. 1995 Jun 30;270(26):15620-7 [7797560.001]
  • [Cites] J Mol Graph. 1996 Feb;14(1):33-8, 27-8 [8744570.001]
  • [Cites] J Bacteriol. 1997 Jun;179(11):3470-81 [9171389.001]
  • [Cites] Eur J Biochem. 1997 Aug 1;247(3):1063-73 [9288932.001]
  • [Cites] Comp Biochem Physiol A Physiol. 1997 Nov;118(3):463-73 [9406429.001]
  • [Cites] Protein Sci. 1998 May;7(5):1083-91 [9605313.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 1998 Jul 1;54(Pt 4):547-57 [9761849.001]
  • [Cites] Adv Microb Physiol. 1998;40:281-351 [9889981.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1240-5 [9990008.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5388-93 [10318893.001]
  • [Cites] Science. 1999 Jul 30;285(5428):751-3 [10427000.001]
  • [Cites] Curr Microbiol. 1999 Oct;39(4):175-9 [10486051.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32 [15572765.001]
  • [Cites] J Biol Chem. 2004 Dec 17;279(51):53136-44 [15381710.001]
  • [Cites] Biochemistry. 2004 Dec 28;43(51):16285-92 [15610022.001]
  • [Cites] J Mol Biol. 2005 May 6;348(3):523-33 [15826651.001]
  • [Cites] J Mol Biol. 2005 May 6;348(3):535-47 [15826652.001]
  • [Cites] Biochemistry. 2005 May 3;44(17):6383-91 [15850372.001]
  • [Cites] Bioinformatics. 2005 Jun 15;21(12):2832-8 [15802286.001]
  • [Cites] J Comput Chem. 2005 Dec;26(16):1668-88 [16200636.001]
  • [Cites] J Comput Chem. 2005 Dec;26(16):1701-18 [16211538.001]
  • [Cites] Proteins. 2005 Dec 1;61(4):704-21 [16231289.001]
  • [Cites] BMC Bioinformatics. 2006;7:316 [16792811.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2007 Jan;63(Pt 1):108-17 [17164533.001]
  • [Cites] Biophys J. 2007 Mar 1;92(5):1792-805 [17172310.001]
  • [Cites] Proteins. 2007 Mar 1;66(4):824-37 [17154422.001]
  • [Cites] Science. 2007 Apr 13;316(5822):254-61 [17431175.001]
  • [Cites] Curr Opin Struct Biol. 2007 Jun;17(3):370-7 [17574831.001]
  • [Cites] J Mol Biol. 2007 Sep 21;372(3):774-97 [17681537.001]
  • [Cites] Science. 2008 Jun 13;320(5882):1428-9 [18556536.001]
  • (PMID = 19128030.001).
  • [ISSN] 1520-4995
  • [Journal-full-title] Biochemistry
  • [ISO-abbreviation] Biochemistry
  • [Language] eng
  • [Databank-accession-numbers] PDB/ 3D6N
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM060371; United States / NHLBI NIH HHS / HL / R01 HL057527; United States / NHLBI NIH HHS / HL / HL47399; United States / NHLBI NIH HHS / HL / HL57527; United States / NIGMS NIH HHS / GM / R01 GM047399; United States / NCI NIH HHS / CA / CA60321; United States / NIGMS NIH HHS / GM / GM60321; United States / NIGMS NIH HHS / GM / GM47399
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Multienzyme Complexes; 0 / Pyrimidines; 155-54-4 / 4,5-dihydroorotic acid; 61H4T033E5 / Orotic Acid; EC 2.1.3.2 / Aspartate Carbamoyltransferase; EC 3.5.2.3 / Dihydroorotase
  • [Other-IDs] NLM/ NIHMS529265; NLM/ PMC3863388
  •  go-up   go-down


86. Weijers G, Starke A, Haudum A, Thijssen JM, Rehage J, De Korte CL: Interactive vs. automatic ultrasound image segmentation methods for staging hepatic lipidosis. Ultrason Imaging; 2010 Jul;32(3):143-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interactive vs. automatic ultrasound image segmentation methods for staging hepatic lipidosis.
  • The aim of this study was to test the hypothesis that automatic segmentation of vessels in ultrasound (US) images can produce similar or better results in grading fatty livers than interactive segmentation.
  • A study was performed in postpartum dairy cows (N=151), as an animal model of human fatty liver disease, to test this hypothesis.
  • Ultrasonic tissue characterization (UTC) parameters--Mean echo level, standard deviation (SD) of echo level, signal-to-noise ratio (SNR), residual attenuation coefficient (ResAtt) and axial and lateral speckle size--were derived using a computer-aided US (CAUS) protocol and software package.
  • Automatic-segmentation algorithms were implemented and it was investigated whether better results could be achieved than with the subjective and time-consuming interactive-segmentation procedure.
  • The automatic-segmentation algorithms were based on both fixed and adaptive thresholding techniques in combination with a 'speckle'-shaped moving-window exclusion technique.
  • This enabled us to study the effect of the applied postprocessing steps on single and multiple linear regressions ofthe various UTC parameters with TAG.
  • Improved correlations for all US parameters were found by using automatic-segmentation techniques.
  • Best speckle-size estimates and overall performance (R2 = 0.71, AUC = 0.94) were achieved by using an SNR-based adaptive automatic-segmentation method (used TAG threshold: 50 mg/g liver wet weight).
  • Automatic segmentation is thus feasible and profitable.
  • [MeSH-minor] Algorithms. Animals. Area Under Curve. Biopsy. Cattle. Disease Models, Animal. Female. Linear Models. ROC Curve. Sensitivity and Specificity. Software. Triglycerides / metabolism. Ultrasonography

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20718244.001).
  • [ISSN] 0161-7346
  • [Journal-full-title] Ultrasonic imaging
  • [ISO-abbreviation] Ultrason Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Triglycerides
  •  go-up   go-down


87. Sakji S, Letord C, Pereira S, Dahamna B, Joubert M, Darmoni J: Drug information portal in Europe: information retrieval with multiple health terminologies. Stud Health Technol Inform; 2009;150:497-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DIP has created specific functionalities related to drug and used specific drugs terminologies and classifications: the ATC classification, the CAS numbers, the French codes CIS, and CIP, as well as trade names and the International Nonproprietary Names of the drugs.

  • MedlinePlus Health Information. consumer health - Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19745361.001).
  • [ISSN] 0926-9630
  • [Journal-full-title] Studies in health technology and informatics
  • [ISO-abbreviation] Stud Health Technol Inform
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Pharmaceutical Preparations
  •  go-up   go-down


88. Avenia N, Ragusa M, Cirocchi R, Puxeddu E, Cavaliere A, De Feo P, Sidoni A, Roila F, Sanguinetti A, Puma F: Surgical treatment of primitive thyroid lymphoma. Tumori; 2009 Nov-Dec;95(6):712-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of primitive thyroid lymphoma.
  • AIMS AND BACKGROUND: Primitive thyroid lymphoma, although rare, is becoming more frequent.
  • Its incidence is increasing, from 0.5% in the sixties to 1-5% of all thyroid neoplasms today.
  • The diagnosis of such neoplasms is not always straightforward.
  • In fact, it is often the result of pathologic findings on a gland resected for an apparently benign disease.
  • Surgical dissection may prove more complicated than in standard cases of thyroidectomy for the possible tight adhesions existing between the gland's capsule and the surrounding structures.
  • METHODS: A retrospective observational analysis was performed to establish whether patients with incidental thyroid lymphomas who underwent total thyroidectomy for another pathology had major surgical complications and worse prognostic results than patients with an accurate preoperative diagnosis.
  • RESULTS: Six cases of thyroid lymphoma were retrospectively reviewed: 4 diffuse large B-cell lymphomas and 2 MALT lymphomas.
  • Of these, 2 were correctly preoperatively identified by fine-needle aspiration biopsy and 4 were an unexpected finding at histology: 3 cases of total thyroidectomy carried out for huge hypothyroid goiter in patients affected by Hashimoto's thyroiditis and in 1 case of total thyroidectomy carried out for anaplastic carcinoma in a patient affected by Hashimoto's thyroiditis.
  • CONCLUSIONS: In our experience, a correct preoperative diagnosis was extremely difficult (33%).
  • In patients who underwent fine-needle aspiration, a correct diagnosis was made in 66% of cases.
  • [MeSH-major] Incidental Findings. Lymphoma / diagnosis. Lymphoma / surgery. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / surgery. Thyroidectomy
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Hashimoto Disease / complications. Humans. Incidence. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / surgery. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / surgery. Male. Middle Aged. Prognosis. Retrospective Studies. Treatment Outcome


89. Ahlstrom U: Work domain analysis for air traffic controller weather displays. J Safety Res; 2005;36(2):159-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Adverse weather conditions have a major impact on National Airspace System (NAS) operations.
  • They create safety hazards for pilots, constrain the usable airspace for air traffic control (ATC), and reduce the overall capacity of the NAS.
  • A system-wide dissemination of weather information to controllers could theoretically improve safety and efficiency.
  • Furthermore, no previous research has empirically evaluated optimal presentation designs for ATC weather displays.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15878775.001).
  • [ISSN] 0022-4375
  • [Journal-full-title] Journal of safety research
  • [ISO-abbreviation] J Safety Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Molander L, Gerstrand M, Rudén C: WikiPharma - a freely available, easily accessible, interactive and comprehensive database for environmental effect data for pharmaceuticals. Regul Toxicol Pharmacol; 2009 Dec;55(3):367-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The database currently contains basic information, i.e. substance name, ATC code(s) and pharmaceutical group(s), for 831 APIs representing 35 different drug classes.
  • [MeSH-minor] Environmental Exposure / adverse effects. Humans. Sweden. Water Pollutants, Chemical / adverse effects

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19720105.001).
  • [ISSN] 1096-0295
  • [Journal-full-title] Regulatory toxicology and pharmacology : RTP
  • [ISO-abbreviation] Regul. Toxicol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Environmental Pollutants; 0 / Water Pollutants, Chemical
  •  go-up   go-down


91. Burnett S, Blakemore SJ: Functional connectivity during a social emotion task in adolescents and in adults. Eur J Neurosci; 2009 Mar;29(6):1294-301
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this fMRI study we investigated functional connectivity between components of the mentalising system during a social emotion task, using psychophysiological interaction (PPI) analysis.
  • In both adults and adolescents, an anterior rostral region of medial prefrontal cortex (arMPFC) involved in mentalising showed greater connectivity with the posterior superior temporal sulcus (pSTS) bordering on the temporo-parietal junction (TPJ) and with anterior temporal cortex (ATC) during social than during basic emotion.
  • This result provides novel evidence that components of the mentalising system interact functionally during a social emotion task.
  • The adolescent group showed stronger connectivity between arMPFC and pSTS/TPJ during social relative to basic emotion than did the adult group, suggestive of developmental changes in functional integration within the mentalising system.

  • MedlinePlus Health Information. consumer health - Family Issues.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OXYGEN .
  • SciCrunch. NeuroSynth: Data: Activation Foci .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Neurosci. 1999 Oct;2(10):861-3 [10491603.001]
  • [Cites] J Comp Neurol. 1999 Aug 2;410(3):343-67 [10404405.001]
  • [Cites] Cogn Behav Neurol. 2005 Mar;18(1):68-78 [15761278.001]
  • [Cites] Neuropsychologia. 2005;43(10):1391-9 [15936784.001]
  • [Cites] Nat Rev Neurosci. 2006 Apr;7(4):268-77 [16552413.001]
  • [Cites] Neuroimage. 2006 Apr 15;30(3):1059-68 [16337813.001]
  • [Cites] Behav Brain Res. 2007 Jul 19;181(1):12-22 [17467816.001]
  • [Cites] Neuroimage. 2007 Jul 15;36(4):1065-73 [17513132.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13507-12 [17679691.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):4028-32 [18322013.001]
  • [Cites] Nat Rev Neurosci. 2008 Apr;9(4):267-77 [18354399.001]
  • [Cites] Hum Brain Mapp. 2008 Jun;29(6):696-710 [17598163.001]
  • [Cites] Neuroimage. 2008 Jul 15;41(4):1345-51 [18495496.001]
  • [Cites] J Cogn Neurosci. 2008 Dec;20(12):2125-36 [18457502.001]
  • [Cites] Nat Rev Neurosci. 2008 Dec;9(12):947-57 [19002191.001]
  • [Cites] Hum Brain Mapp. 2009 Jan;30(1):24-37 [17979124.001]
  • [Cites] Cereb Cortex. 2009 Mar;19(3):640-57 [18653667.001]
  • [Cites] Soc Cogn Affect Neurosci. 2007 Jun;2(2):130-9 [17710201.001]
  • [Cites] J Cogn Neurosci. 2009 Sep;21(9):1736-50 [18823226.001]
  • [Cites] Soc Cogn Affect Neurosci. 2006 Sep;1(2):107-21 [18985123.001]
  • [Cites] Soc Cogn Affect Neurosci. 2007 Sep;2(3):217-26 [18985143.001]
  • [Cites] Psychol Rep. 2002 Dec;91(3 Pt 1):743-57 [12530718.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2003 Mar 29;358(1431):459-73 [12689373.001]
  • [Cites] Eur J Neurosci. 2003 Jun;17(11):2475-80 [12814380.001]
  • [Cites] Neuroimage. 2003 Aug;19(4):1835-42 [12948738.001]
  • [Cites] Brain Res Cogn Brain Res. 2003 Dec;18(1):48-57 [14659496.001]
  • [Cites] Neuroreport. 2004 Feb 9;15(2):219-23 [15076740.001]
  • [Cites] Brain Res. 1979 Mar 16;163(2):195-205 [427544.001]
  • [Cites] Neurosci Lett. 1982 Dec 13;33(3):247-52 [7162689.001]
  • [Cites] Arch Gen Psychiatry. 1994 Jun;51(6):477-84 [8192550.001]
  • [Cites] Neuroreport. 1995 Sep 11;6(13):1741-6 [8541472.001]
  • [Cites] Exp Brain Res. 1997 Jul;115(3):430-44 [9262198.001]
  • [Cites] J Comp Neurol. 1997 Oct 20;387(2):167-78 [9336221.001]
  • [Cites] Neuroimage. 1997 Oct;6(3):218-29 [9344826.001]
  • [Cites] Percept Mot Skills. 2004 Oct;99(2):371-91 [15560325.001]
  • (PMID = 19302165.001).
  • [ISSN] 1460-9568
  • [Journal-full-title] The European journal of neuroscience
  • [ISO-abbreviation] Eur. J. Neurosci.
  • [Language] ENG
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] S88TT14065 / Oxygen
  • [Other-IDs] NLM/ PMC2695858
  •  go-up   go-down


92. Motti CA, Bourguet-Kondracki ML, Longeon A, Doyle JR, Llewellyn LE, Tapiolas DM, Yin P: Comparison of the biological properties of several marine sponge-derived sesquiterpenoid quinones. Molecules; 2007;12(7):1376-88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SAR analyses indicate that a hydroxyquinone functionality and a short, hydroxide/alkoxide side-chain atC-20 is preferred for inhibition of PPDK activity, and that a larger amine side-chain at C-20 is tolerated for PLA2 inhibitory activity.
  • [MeSH-minor] Animals. Anti-Inflammatory Agents / pharmacology. Digitaria / drug effects. Dose-Response Relationship, Drug. Herbicides / pharmacology. Humans. Models, Chemical

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17909493.001).
  • [ISSN] 1420-3049
  • [Journal-full-title] Molecules (Basel, Switzerland)
  • [ISO-abbreviation] Molecules
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Herbicides; 0 / Quinones; 0 / Sesquiterpenes
  •  go-up   go-down


93. Hoffmann S, Wunderlich A, Celik I, Maschuw K, Hassan I, Hofbauer LC, Zielke A: Paneling human thyroid cancer cell lines for candidate proteins for targeted anti-angiogenic therapy. J Cell Biochem; 2006 Jul 1;98(4):954-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paneling human thyroid cancer cell lines for candidate proteins for targeted anti-angiogenic therapy.
  • Such therapy has raised hopes for patients with undifferentiated thyroid carcinomas, who are facing a grave prognosis with a survival of only months.
  • In this study, in vivo growth of xenografted human thyroid carcinomas unexpectedly responded quite differently to neutralizing anti-vascular endothelial growth factor (VEGF) antibody.
  • Consequently, a panel of anti-angiogenic factors was addressed in a representative sample of thyroid carcinoma lines.
  • Quantification of VEGF, FGF-2, and endostatin revealed a wide range of concentrations from 500 to 4,200 pg/ml VEGF, 5 to 60 pg/ml FGF-2, and 50 to 300 pg/ml endostatin, not related to a particular histologic thyroid carcinoma background.
  • These data highlight the complex regulation of angiogenesis in thyroid carcinoma cell lines and suggest that the array of angiogenic factors differs markedly between individual cell lines.
  • For the first time, angiostatin, endostatin, and possibly also aaATIII are identified as novel candidate regulators of angiogenesis in thyroid carcinoma cells.
  • [MeSH-major] Angiogenesis Inhibitors / pharmacology. Carcinoma / metabolism. Neoplasm Proteins / metabolism. Neovascularization, Pathologic / metabolism. Thyroid Neoplasms / metabolism

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 Wiley-Liss, Inc.
  • (PMID = 16475167.001).
  • [ISSN] 0730-2312
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Neoplasm Proteins
  •  go-up   go-down


94. Katz A, Soodeen RA, Bogdanovic B, De Coster C, Chateau D: Can the quality of care in family practice be measured using administrative data? Health Serv Res; 2006 Dec;41(6):2238-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DATA SOURCES/STUDY SETTING: The Population Health Research Data Repository (Repository) housed at the Manitoba Centre for Health Policy which includes physician claims, hospital discharge abstracts, pharmaceutical use (Drug Program Information Network (DPIN)), and the Manitoba Immunization Monitoring Program (MIMS) for all residents of Manitoba, Canada who used the health care system during the 2001/02 fiscal year.
  • We extracted data based on the ICD-9-CM codes and ATC-class drugs prescribed and then linked them to the Physician Resource Database.
  • PRINCIPAL FINDINGS: Using administrative health data we were able to develop and measure eight indicators of quality of care covering both preventive care services and chronic disease management.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2000 May 17;283(19):2579-84 [10815125.001]
  • [Cites] Can J Aging. 2005 Spring;24 Suppl 1:153-70 [16080132.001]
  • [Cites] N Engl J Med. 2001 Jun 28;344(26):2021-5 [11430334.001]
  • [Cites] Qual Health Care. 2001 Sep;10(3):152-8 [11533422.001]
  • [Cites] Med Care. 2002 Feb;40(2):155-65 [11802088.001]
  • [Cites] Diabetes Care. 2002 Mar;25(3):512-6 [11874939.001]
  • [Cites] Health Policy. 2002 Jun;60(3):201-18 [11965331.001]
  • [Cites] Can J Cardiol. 2003 Jan;19(1):38-45 [12571693.001]
  • [Cites] Can J Public Health. 2002 Nov-Dec;93 Suppl 2:S15-20 [12580385.001]
  • [Cites] Health Serv Res. 2003 Jun;38(3):831-65 [12822915.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2635-45 [12826639.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):406-10 [14736934.001]
  • [Cites] Soc Sci Med. 2004 Jun;58(11):2231-41 [15047080.001]
  • [Cites] Ann Fam Med. 2004 Mar-Apr;2 Suppl 1:S3-32 [15080220.001]
  • [Cites] Health Serv Res. 2004 Jun;39(3):511-30 [15149476.001]
  • [Cites] CMAJ. 2004 Aug 17;171(4):339-42 [15313992.001]
  • [Cites] CMAJ. 2004 Oct 26;171(9):1013, 1015 [15505241.001]
  • [Cites] Med Care. 1993 Mar;31(3):201-12 [8450678.001]
  • [Cites] J Clin Epidemiol. 1995 Aug;48(8):999-1009 [7775999.001]
  • [Cites] Soc Sci Med. 1996 May;42(9):1273-81 [8733197.001]
  • [Cites] N Engl J Med. 1996 Sep 26;335(13):966-70 [8782507.001]
  • [Cites] Am J Med Qual. 1997 Summer;12(2):83-93 [9161055.001]
  • [Cites] J Clin Epidemiol. 1997 Jun;50(6):711-8 [9250269.001]
  • [Cites] J Fam Pract. 1998 May;46(5):377-89 [9597995.001]
  • [Cites] J Public Health Med. 1998 Dec;20(4):414-21 [9923948.001]
  • [Cites] Qual Health Care. 1998 Dec;7 Suppl:S45-50 [10339035.001]
  • [Cites] Health Aff (Millwood). 2004 Jan-Jun;Suppl Web Exclusives:W4-184-97 [15451981.001]
  • [Cites] Health Serv Res. 2005 Aug;40(4):953-6 [16033486.001]
  • [Cites] Int J Qual Health Care. 2000 Aug;12(4):281-95 [10985266.001]
  • (PMID = 17116118.001).
  • [ISSN] 0017-9124
  • [Journal-full-title] Health services research
  • [ISO-abbreviation] Health Serv Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1955305
  •  go-up   go-down


95. Skvrce NM, Arapović S, Krnić D, Sarinić VM, Zezelić S, Bagatin K, Leventić J, Tomić S: Adverse drug reactions of psycopharmacs. Psychiatr Danub; 2010 Sep;22(3):441-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The objective of analysis of ADRs caused by drugs that pertain to the ATC group N (nervous system), as reported to the Croatian Agency for Medicinal Products and Medical Devices for the period from March 2005 to December 2008, was to examine the types of ADRs collected in said period, the profile of reporters and the possible impacts this could have on prescribing this group of medicinal products in the future.
  • Drugs causing ADRs were grouped according to the ATC drug classification, and subsequently entered into a database.
  • Data were analyzed in respect of total number, gender, age, type, seriousness, expectedness, outcome, system organ class, suspected drug and reporter.
  • RESULTS: The findings showed that 15% of all reported ADRs were caused by drugs from the ATC group N. 60% of these were caused by drugs belonging to the ATC subgroups N05 (psycholeptics) and N06A (antidepressants).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20856189.001).
  • [ISSN] 0353-5053
  • [Journal-full-title] Psychiatria Danubina
  • [ISO-abbreviation] Psychiatr Danub
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Psychotropic Drugs
  •  go-up   go-down


96. Ducic Y, Oxford L: Transcervical elective superior mediastinal dissection for thyroid carcinoma. Am J Otolaryngol; 2009 Jul-Aug;30(4):221-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcervical elective superior mediastinal dissection for thyroid carcinoma.
  • OBJECTIVES: To review our results with elective superior mediastinal dissections for thyroid carcinomas.
  • METHODS: We searched operative case logs for all patients with thyroid carcinoma treated with an elective superior mediastinal dissection by the senior author (Y.D.) during a 6-year period.
  • Elective superior mediastinal dissections were performed when the frozen section was consistent with anaplastic or medullary carcinoma or with a well-differentiated carcinoma when there was fixation of the primary tumor to the laryngotracheal complex, there was overt clinically evident paratracheal and/or cervical adenopathy, or the primary tumor measured greater than 2.0 cm in dimension.
  • RESULTS: Thirty-one patients meeting the above criteria were reviewed, and superior mediastinal disease was present in 19 patients (61.3%).
  • Superior mediastinal nodes were positive in 13 (65%) of 20 patients with papillary carcinoma, 0 of 4 with follicular thyroid carcinoma, 4 of 5 patients with medullary thyroid carcinoma, and 2 of 2 patients with anaplastic thyroid carcinoma.
  • Patients with follicular carcinoma had a lower incidence of mediastinal disease (0%) compared with nonfollicular thyroid carcinoma (70.4%), P = .02.
  • Patients with cervical metastasis had an increased incidence of superior mediastinal disease (100% vs 53.3%).
  • CONCLUSIONS: Elective transcervical superior mediastinal dissection was commonly positive in patients with papillary, medullary, and anaplastic thyroid carcinomas.
  • [MeSH-major] Elective Surgical Procedures / methods. Mediastinum / surgery. Thyroid Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19563930.001).
  • [ISSN] 1532-818X
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Liu J, Brown RE: Morphoproteomics demonstrates activation of mTOR pathway in anaplastic thyroid carcinoma: a preliminary observation. Ann Clin Lab Sci; 2010;40(3):211-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphoproteomics demonstrates activation of mTOR pathway in anaplastic thyroid carcinoma: a preliminary observation.
  • The mammalian target of rapamycin (mTOR) signaling pathway was studied using immunohistochemical stains on paraffin-embedded tumor tissue from two patients with anaplastic thyroid carcinoma (ATC) and on paraffin-embedded normal thyroid tissue from 23 control patients.
  • Increased expression of Ki-67, Skp2, and cyclin D1, decreased expression of p27(kip1), and increased mitotic index (MI) were noted in the ATCs in comparison with those of normal thyroid tissue.
  • These preliminary findings warrant future studies in a large series of patients with ATC to evaluate a possible molecular basis for treating chemoradioresistant ATC.
  • [MeSH-major] Carcinoma / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. Protein-Serine-Threonine Kinases / metabolism. Proteomics. Signal Transduction. Thyroid Gland / metabolism. Thyroid Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20689131.001).
  • [ISSN] 1550-8080
  • [Journal-full-title] Annals of clinical and laboratory science
  • [ISO-abbreviation] Ann. Clin. Lab. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCND1 protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Ki-67 Antigen; 0 / S-Phase Kinase-Associated Proteins; 136601-57-5 / Cyclin D1; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa; EC 3.1.4.4 / Phospholipase D; EC 3.1.4.4 / phospholipase D1
  •  go-up   go-down


98. Luksiene Z, Buchovec I, Paskeviciute E: Inactivation of several strains of Listeria monocytogenes attached to the surface of packaging material by Na-Chlorophyllin-based photosensitization. J Photochem Photobiol B; 2010 Dec 2;101(3):326-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study was focused on the possibility to inactivate thermosensitive Listeria monocytogenes ATC(L3)C 7644 and thermoresistant 56 Ly strain by Na-Chlorophyllin (Na-Chl)-based photosensitization in vitro and on the surface of packaging.
  • In conclusion, both strains of L. monocytogenes can be effectively inactivated by photosensitization in vitro and on the surface of packaging.

  • Hazardous Substances Data Bank. SODIUM HYPOCHLORITE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier B.V.
  • (PMID = 20801669.001).
  • [ISSN] 1873-2682
  • [Journal-full-title] Journal of photochemistry and photobiology. B, Biology
  • [ISO-abbreviation] J. Photochem. Photobiol. B, Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Chlorophyllides; 0 / Photosensitizing Agents; 15611-43-5 / chlorophyllin; DY38VHM5OD / Sodium Hypochlorite
  •  go-up   go-down


99. Yano H, Kubota T, Miyamoto H, Okada T, Scheeres D, Takagi Y, Yoshida K, Abe M, Abe S, Barnouin-Jha O, Fujiwara A, Hasegawa S, Hashimoto T, Ishiguro M, Kato M, Kawaguchi J, Mukai T, Saito J, Sasaki S, Yoshikawa M: Touchdown of the Hayabusa spacecraft at the Muses Sea on Itokawa. Science; 2006 Jun 2;312(5778):1350-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After global observations of asteroid 25143 Itokawa by the Hayabusa spacecraft, we selected the smooth terrain of the Muses Sea for two touchdowns carried out on 19 and 25 November 2005 UTC for the first asteroid sample collection with an impact sampling mechanism.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16741113.001).
  • [ISSN] 1095-9203
  • [Journal-full-title] Science (New York, N.Y.)
  • [ISO-abbreviation] Science
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Wirtz VJ, Dreser A, Gonzales R: Trends in antibiotic utilization in eight Latin American countries, 1997-2007. Rev Panam Salud Publica; 2010 Mar;27(3):219-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To describe the trends in antibiotic utilization in eight Latin American countries between 1997-2007 METHODS: We analyzed retail sales data of oral and injectable antibiotics (World Health Organization (WHO) Anatomic Therapeutic Chemical (ATC) code J01) between 1997 and 2007 for Argentina, Brazil, Chile, Colombia, Mexico, Peru, Uruguay, and Venezuela.
  • The kilogram sales of each antibiotic were converted into defined daily dose per 1 000 inhabitants per day (DID) according to the WHO ATC classification system.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20414511.001).
  • [ISSN] 1680-5348
  • [Journal-full-title] Revista panamericana de salud pública = Pan American journal of public health
  • [ISO-abbreviation] Rev. Panam. Salud Publica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down






Advertisement